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Summary
Anaesthesia may alter acutely the disposition of drugs 
in the body. This may be produced by changes in hepatic 
blood flow, by changes in hepatic drug-metabolising 
enzyme activity or by changes in the distribution of the 
drug in the body. The known effect of anaesthesia on 
these determinants is described. The control of and 
factors affecting hepatic blood flow are discussed, as 
are the methods of measuring it. Hepatic drug 
metabolising enzymes are described. Their activity, 
mathematical models,methods of assessment and factors 
altering activity are discussed.
The effect of four different anaesthetics was studied 
using a canine model with propranolol administered as 
the test drug. Five days after surgery to insert portal 
venous andfemoral arterial and venous cannulae, each 
animal was studied on three consecutive days using 
dual-route administration of propranolol. That is, 
simultaneous administration of radiolabelled intravenous 
propranolol and unlabelled intraportal propranolol. The 
dogs were studied while awake on the 1st and 3rd days 
and while anaesthetised on the 2nd day. The anaesthetic 
agents studied were halothane, isoflurane, enflurane and 
a fentanyl, atracurium and nitrous oxide technique.
Blood samples were taken at regular intervals for
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determination of plasma propranolol and plasma labelled 
propranolol concentrations. The pharmacokinetic 
variables for each dog were calculated from these 
concentrations.
All four anaesthetic regimens produced a decrease in the 
intrinsic clearance (enzyme dependent) of 50-60% 
reflecting a marked inhibition of the enzyme function. 
The systemic (intravenous) clearance decreased by some 
3 0-40%. This was due in part to the fall in hepatic 
blood flow of 25-35% but also as a result of the 
decreased enzyme activity.
An additional study to evaluate this technique in man 
was undertaken. This involved a randomised double blind 
study of the effect on dual-route propranolol (oral and 
IV) of a known enzyme inhibitor, cimetidine, a 
prostaglandin analogue, enprostil, which may have 
altered hepatic blood flow and a placebo. Inhibition of 
propranolol metabolism was produced by cimetidine but no 
effect on hepatic blood flow was found with either 
enprostil or cimetidine.
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1.1 Background
The practice of anaesthesia involves the acute 
administration, intravenously or by inhalation, of drugs 
to produce and maintain sleep. The development and 
clinical use of anaesthetic agents has demanded that the 
pharmacology and the physiological effects of each drug 
be known in great detail. Historically this has led to a 
close association between anaesthesia and the 
disciplines of pharmacology and physiology. Early
examples of this may be found in the dose-response 
relationships described by Snow for Chloroform and 
Guedel's planes of anaesthesia for ether. In a review of 
the history of pharmacokinetics, Wagner (1) cites
contributions from the anaesthetic literature at all
stages of the development of this discipline. This 
included descriptions of the uptake, distribution and 
elimination of inhalational agents including ether (2,3) 
and halothane (4,5), and intravenous agents such as 
thiopentone (6).
Over the years the anaesthetists' knowledge of drugs 
has paralleled the advances in pharmacological methods. 
The development of chromatographic systems which are
capable of measuring very small concentrations of drug 
in biological fluids has made the anaesthetist aware of 
the prolonged elimination time for some anaesthetic
agents and, therefore, the potential for drug 
interaction in the post-operative period. The ability to 
determine the changes in plasma concentration of a drug 
over a period of time has led to the development of 
mathematical models to describe the distribution and 
elimination of drugs. These pharmacokinetic principles 
were applied at an early stage to drugs used in 
anaesthesia, and, more recently, applied to the design 
of infusion regimens for intravenous anaesthesia.
The potential for two drugs interacting to produce an 
inhibition or potentiation of effect has been known for 
many years. In hypotensive anaesthesia, for example, 
halothane was used to potentiate the hypotension
produced by ganglion blockade and, therefore to minimise 
the amount of ganglion blocking drug required. However, 
apart from drug interactions which produce a 
physiological response, such as changes in blood
pressure, heart rate or respiratory rate, the acute
action of anaesthesia on other drugs is not well 
described. This may arise from the assumption that the 
effect of anaesthesia and anaesthetic agents will be 
transient and that changes will not persist into the 
post-operative period. There is little evidence to 
support this assumption.
The aim of these studies is to determine the effect
of anaesthetic agents on drug disposition during and
after anaesthesia.
20
1.2 Potential interactions in anaesthesia
The area of study of this project is the effect of 
anaesthesia on the hepatic determinants of drug 
disposition. Accordingly, the effects on renal or 
pulmonary drug clearance will not be dealt with in 
detail.
There are three mechanisms affecting drug disposition 
which may be altered by anaesthesia
a) Drug metabolism by hepatic enzyme systems,
b) Hepatic blood flow, that is the rate of delivery of a 
drug to the liver
c) alteration of the distribution of a drug in the body 
by changes in volume of distribution or degree of 
protein binding.
These three determinants will be dealt with separately.
21
1.3 Metabolism
1.3.1 Enzyme function and Biotransformation of drugs
The biotransformation of drugs describes the process 
of alteration of the chemical structure and biological 
properties of a drug by metabolism. The end result of
this process is usually a more polar compound which is
easier to excrete. Most organic compounds are slowly 
eliminated from the body if they remain unchanged
chemically. The physico-chemical properties of each
compound will determine the extent of distribution 
throughout the body. A highly lipid soluble compound 
would be excreted slowly by the kidney unless rendered 
more water soluble and polar by metabolism. 
Biotransformation does not necessarily inactivate a drug 
as some drugs require metabolism to activate them and 
others have active metabolites.
The hepatic enzymes are the main mechanism for 
removal of drugs from the body. The basic reactions 
involved are oxidation, reduction, hydroxylation and 
conjugation. These are usually classified as Phase I 
(oxidation, reduction and hydroxylation) and Phase II 
reactions.
Phase I reactions : Oxidation reactions involve the
22
loss of electrons, usually by addition of an oxygen atom 
to the substrate, and are catalysed by hepatic 
microsomal enzymes known collectively as the cytochrome 
P-450 system or mixed function oxidases. This group of 
enzymes are discussed below. Reductive reactions involve 
the gain of electrons and are much less common. Examples 
of reductive reactions in anaesthesia include the 
metabolism of azo- and nitro- groups to their
corresponding amines as in the breakdown of fazadinium 
and nitrazepam respectively. The dehalogenation of 
halothane to trifluoroethane is a reductive process 
which is normally a minor pathway of metabolism but may 
be of importance in the development of halothane 
hepatotoxicity. Hydrolysis of esters and amides by 
esterases and amidases occurs in many tissues including 
the liver. Examples in anaesthesia include the
metabolism of ester local anaesthetic agents, pethidine 
and atropine.
Phase II reactions : Conjugation reactions are
essentially synthetic. They involve the conjugation of a 
drug, or drug metabolite produced by a Phase I reaction, 
to form an inactive, polarised, water soluble compound 
for excretion. The substrates commonly involved include 
glucuronic acid, sulphates, acetyl groups, amino acids
such as glycine and methyl groups. These compounds are
then excreted in the bile or the urine.
23
P450 enzyme system : The P-450 system, or mixed function 
oxidase system, is able to metabolise a wide range of 
substances, ie has broad substrate specificity. The 
amount and activity of the system may also be increased 
or decreased by exposure to drugs. Increased activity 
and concentration of enzymes, induction, is associated 
classically with barbiturate administration but this 
response is produced by many drugs and chemicals. The 
range of enzymes induced varies. Barbiturates produce a 
generalised increase of enzyme activity but ethanol and 
cigarette smoke produce a narrower band of increased 
activity. The activity of the P-450 system is decreased 
by the administration of cimetidine and other drugs. A 
more comprehensive description of the P450 system is
given in Chapter 3.
1.3.2 Actions of anaesthetic agents on
drug metabolism
In vitro , animal and human studies
The effect of anaesthesia and surgery on metabolism 
of several model compounds has been described. The 
majority of human studies have been undertaken between 3 
and 8 days after anaesthesia and this introduces a
series of variables which make interpretation of the 
results very difficult. This is perhaps best illustrated
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in the study by Pessayre and colleagues (7) who reported 
that short operations, less than 2 hours, caused an 
increase in antipyrine metabolism, whereas, long 
operations, greater than 4 hours, caused a decrease in 
antipyrine metabolism. However, this is only one aspect
of their population of patients who had a variety of 
surgical procedures, different intra- and post­
operative drug therapies, different durations of 
parenteral infusions and a variety of post-operative 
complications any of which may have an influence on drug 
metabolism. Nimmo and colleagues (8) demonstrated a 
decrease in antipyrine half life one week after 
halothane anaesthesia, suggesting microsomal enzyme 
induction. The antipyrine half life had returned to the 
pre-operative control value at four weeks. Duvaldestin 
and co-workers (9) found a similar decrease in
antipyrine half, life 4-8 days after halothane or 
neurolept anaesthesia. The physiological response to
surgery results in changes in the haemodynamics and in 
the protein binding of drugs which would be a major 
factor in the altered drug disposition found in these 
studies. It is therefore difficult to attribute all or 
indeed any of these changes found at 3-8 days after 
surgery to the action of anaesthetic agents. The field 
of interest of this project, however is limited to the 
effects of anaesthesia in the immediate perioperative 
period and the acute effects of the various anaesthetic
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agents are reviewed.
a) Halothane
The effect of halothane on hepatic function has been 
extensively investigated in relation to halothane 
hepatitis and has provided some insight to the 
mechanisms involved in this process. This in turn has 
established a basis from which to assess the effect of 
halothane on drug metabolism. In 1971 Brown described 
the effect of halothane on the ability of isolated rat 
hepatocytes to metabolize drugs (10). He demonstrated a 
marked difference in effect of halothane on Type 1 and 
on Type 2 oxidative reactions. Type 1 reactions, for 
example aminopyrine metabolism, were inhibited by the 
presence of halothane whereas some enhancement was shown 
on Type 2 reactions such as the breakdown of analine. 
This study concluded that halothane produced an effect 
on part of the cytochrome P450 enzyme system involved in 
drug metabolism. In a subsequent study, Brown showed a 
dose-related, non-competitive inhibition of rat
microsomal glucuronyltransferase activity in the
presence of halothane, methoxyflurane, chloroform or 
diethyl ether (11). Halothane has also been shown to 
selectively inhibit the N-dealkalation of bupivacaine by 
isolated rat hepatocytes (12). Aune and colleagues (13) 
in an in vitro study demonstrated a dose related 
inhibition of antipyrine oxidation and, to a lesser
26
extent, of paracetamol conjugation in the presence of 
halothane. An in vitro study has demonstrated that 
exposure to halothane produces an inhibition of P450 
activity (14).
More recent work using animal models has confirmed 
these basic observations. Dale and colleagues (15) 
demonstrated a decrease in NADPH- cytochrome reductase 
activity in rats following exposure to 0.05 MAC 
halothane. Fish and Rice (16), again in rats, showed an 
inhibition of enflurane metabolism, as measured by serum 
inorganic fluoride production, during simultaneous 
exposure to halothane and enflurane. The 
pharmacokinetics of diazepam and its metabolism were 
altered by halothane anaesthesia in rats (17). In 
contrast, Berger and colleagues (18) found halothane 
anaesthesia had no effect on the pharmacokinetics of 
theophylline in dogs, but in this study sampling may not 
have been continued for long enough to accurately define 
the kinetic parameters (19). Wood and Wood (20) found a 
marked, dose related decrease in the rate of aminopyrine 
metabolism in rats at 2 and 24 hours after halothane 
anaesthesia suggesting a much longer effect than had 
been previously demonstrated. In a study comparing the 
effect of four different anaesthetic agents on 
post-operative hepatic function in cirrhotic and 
non-cirrhotic rats, Baden and colleagues (21) 
demonstrated a minimal degree of hepatic dysfunction 48
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hours after anaesthesia in both groups and with each 
anaesthetic agent (halothane, enflurane, isoflurane or 
fentanyl). Halothane has been shown in studies using a 
dog model to affect the metabolism of several drugs 
including pethidine (22), lignocaine (23,24), and
verapamil (25) and to decrease the extraction of
indocyanine green (26). In a sheep model, halothane 
anaesthesia has been shown to cause a marked but short 
lasting decrease in the hepatic clearance of pethidine 
(27) and a reduction in the hepatic extraction and 
clearance of chlormethiazole (28).
There have been relatively few studies of human 
hepatic metabolism during anaesthesia. Two studies 
(29,30) found a decrease in the production of halothane 
metabolites during halothane anaesthesia, and proposed 
that halothane inhibited its own dehalogenation. Plasma 
fentanyl concentrations have been demonstrated in man to 
be markedly elevated during halothane anaesthesia when 
compared with a control group (31,32). Fish and Rice 
(33) demonstrated a similar degree of inhibition of 
enflurane metabolism in man during concurrent halothane 
administration as they had previously found in rats.
Halothane anaesthesia has been shown to alter the
pharmacokinetics of lignocaine in man (34) but not of 
thiopentone (35).
28
b) Enflurane
The effects of enflurane on hepatic drug metabolism 
have been studied less extensively than those of 
halothane. Aune and colleagues (13) found a similar 
degree of inhibition of antipyrine and paracetamol 
metabolism in rat hepatocytes exposed to enflurane or 
halothane. DaRocha-Reis (3 6) found no increase in rat 
microsomal proteins following exposure to enflurane at 
various concentrations for increasing lengths of time. 
Dale and colleagues (15) showed exposure to enflurane 
had little effect on rat microsomal enzyme activity. 
Wood and Wood (20) found enflurane anaesthesia had no 
effect on aminopyrine metabolism in the rat and Berger 
and colleagues (18) found no alteration in theophylline 
pharmacokinetics in dogs. However, Merin and colleagues 
found a reduction in the clearance of verapamil in dogs
during enflurane anaesthesia.
There are few studies of the acute effects of
enflurane in man. Berman and co-workers (37) found
altered cortisol metabolism in a group of volunteers 
immediately following enflurane anaesthesia. They showed 
a shift in the ratio of the 6-OHF to 17-OHCS metabolites 
which they suggested was due to induction of hepatic 
microsomal enzymes. It is possible that this change was 
due, in part, to inhibition of hepatic clearance of
metabolites. Ghoneim and van Hamme (38) found enflurane 
anaesthesia had no effect on the pharmacokinetics of
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thiopentone. Schuttler and colleagues (39) demonstrated 
that, in contrast to fentanyl anaesthesia, enflurane 
anaesthesia had no effect on etomidate pharmacokinetics. 
Oikkonen and colleagues (40) did not find consistent 
changes in antipyrine metabolism immediately after 
enflurane or balanced anaesthesia. However, this study 
included .patients who had factors which may have 
influenced hepatic enzyme activity, such as recent 
anaesthesia and concurrent administration of drugs known 
to induce enzymes. Antipyrine clearance and half-life 
were unchanged 4 and 7 days after enflurane anaesthesia 
(41) .
c) Isoflurane
There are as yet relatively few studies of the effect 
of isoflurane on drug metabolism. Wood and Wood (20) 
demonstrated that isoflurane anaesthesia decreased the 
elimination rate of aminopyrine in rats but to a smaller 
and shorter lasting extent than halothane. 
Fiserova-Bergerova (42) demonstrated in rats exposed to 
sub-anaesthetic concentrations of isoflurane and 
halothane or nitrous oxide and halothane, that 
isoflurane inhibited the oxidative metabolism of
halothane but enhanced the reductive metabolism. A 
subsequent study confirmed this effect but demonstrated 
that it was transient by showing that the metabolism of 
halothane administered 4 or 24 hours after the
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isoflurane was unaffected (43). Nitrous oxide had no 
effect on halothane metabolism.
d) Acute versus chronic exposure to volatile agents
In a manner similar to the influence of time between 
exposure to volatile agents and time of testing drug 
metabolism described above, the duration and extent of 
exposure to these agents also appears to alter drug 
metabolism. In vitro studies with rat hepatocytes have 
demonstrated an inductive effect following prolonged 
exposure to low dose ether (44,45) but no effect 
following exposure to halothane (45) or methoxyflurane 
(44) . Antipyrine metabolism has been shown to be 
increased in anaesthetists and theatre personnel 
regularly exposed to volatile anaesthetic agents 
(46,47,48). In one of these studies (47) the subjects 
were not exposed to volatile agents for three weeks and 
their antipyrine clearance decreased. The
biotransformation of halothane by anaesthetists with 
regular exposure to anaesthetic agents has been shown 
not to be altered significantly (29,49).
e) Intravenous induction agents
As intravenous induction agents are relatively rarely
are
used alone to provide anaesthesia there^few descriptions 
of their effect in isolation on drug disposition. The 
enzyme inducing effect of barbiturates has not been
31
demonstrated following single exposure to thiopentone or 
methohexitone during anaesthesia (50).
f) Opioids
Alteration of hepatic enzyme function by opioid drugs 
has not been demonstrated in vivo . An in vitro study 
using human liver microsomes has suggested a competitive 
inhibition of desipramine hydroxylation by both fentanyl 
and alfentanil (51).
1.3.3 Summary
Anaesthetic agents have been shown to produce an 
effect on hepatic microsomal enzyme activity in vitro 
and in animal and human studies. Halothane is the most 
extensively investigated agent. An inhibitory action on 
the oxidative metabolism of many drugs has been
demonstrated in all three types of study during or 
following exposure to halothane. The effect of enflurane 
is defined less clearly. Some studies have suggested a 
similar effect to that found with halothane but the 
majority have found enflurane anaesthesia to have little 
effect on hepatic drug metabolism. There are few studies 
of the effect of isoflurane anaesthesia but it appears 
that isoflurane may have a similar inhibitory effect to 
that of halothane. Chronic exposure to a low dose of
32
volatile agent appears to cause hepatic enzyme 
induction. Intravenous anaesthetic agents and opioids 
have undergone only limited study but do not appear to 
have a major effect on hepatic enzymes.
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1.4 Hepatic blood flow
1.4.1 Anatomy and regulation
The liver receives its blood supply from the hepatic 
artery and the portal vein. The hepatic artery arises 
from the coeliac artery and supplies 30-40% of the total 
hepatic blood flow. The portal vein is formed by the
confluence of the superior mesenteric and splenic (hence 
inferior mesenteric) veins and thus carries blood from 
all areas of the alimentary tract within the abdomen as 
well as supplying 60-70% of hepatic blood flow. The 
hepatic artery and portal vein run in parallel and
undergo serial branching throughout the liver. There is 
no vascular communication between the right and left 
halves of the liver. The terminal branches of the portal 
vein drain into the hepatic sinusoids.
Hepatic blood flow is determined principally by 
hepatic arterial resistance for arterial flow and for
venous flow by splanchnic vascular and portal vascular 
resistance. The control of these determinants appears to 
be mainly extrinsic. There is, however, a relationship 
of reciprocity between the hepatic arterial and portal 
flows which has a hydrodynamic basis. This interaction 
results in an increased resistance in one circuit in 
response to an increased flow through the other. It is 
possible that hepatic haemodynamics are geared towards
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maintenance of portal venous pressure rather than portal 
blood flow. Neural control of hepatic flow is exerted by 
both the sympathetic and vagal nerves but this is 
relatively weak when compared with other organs.
The extrinsic controls of hepatic blood flow are 
principally metabolic in origin and include the portal 
venous pH, pC02 and p02. These substances are all likely 
to be present after a meal and in part account for the 
increased blood flow found with increased hepatic 
metabolic activity.
The anatomy, regulation and measurement of hepatic 
blood flow are described more fully in Chapter 2.
1.4.2 Effect of anaesthetic agents on hepatic 
blood flow
Animal and human studies
a) Halothane
The effect of halothane on regional circulation was 
initially investigated as a possible explanation of 
hepatic damage following anaesthesia. Following the 
description of a decrease in splanchnic circulation in 
man during halothane anaesthesia by Epstein and 
colleagues in 1965 (52), the same group assessed the 
effect on hepatic blood flow using indocyanine green 
extraction (53). They found that halothane anaesthesia
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caused a 25-30 % fall in hepatic blood flow from a
pre-anaesthetic control value. Using a dog model to 
measure hepatic blood flow by the disappearance of 
radiolabelled Xenon injected into the portal vein, 
Ahlgren and colleagues (54) found portal blood flow 
decreased with increasing depth of halothane anaesthesia
during spontaneous and assisted ventilation. Gelman (55)
using a colloidal gold technique to measure hepatic 
blood flow in man, found halothane anaesthesia in the 
absence of surgery resulted in a decrease to 84% of 
control value. When these measurements were repeated 
during surgery it was noted that body surface surgery 
cause a further fall to 76% of control whereas upper
abdominal surgery resulted in a fall to 42% of the
control value of hepatic blood flow. Thulin and 
colleagues (56) using an electromagnetic flow probe in 
dogs described a decrease to 50-60% of control value in 
both hepatic artery and portal vein flow during 
halothane anaesthesia. They also noted a decrease in 
splanchnic oxygen flow and uptake of around 50%. Hughes 
and colleagues (57) also using electromagnetic flow 
probes in greyhounds found a dose related decrease in 
hepatic arterial, portal venous and total hepatic blood 
flows. They showed no change in hepatic arterial 
resistance or hepatic oxygen consumption. Tranquilli and 
co-workers (58) using a microsphere technique, 
demonstrated a dose related decrease in regional blood
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flow, including splanchnic but not hepatic arterial 
flow, during halothane anaesthesia in swine. They noted, 
however, that the percentage of the cardiac output 
received by the liver was increased to 162% of the 
control value. Using a similar microsphere technique in 
dogs, Gelman and colleagues (59) found a dose related 
decrease in pre-portal flow during halothane 
anaesthesia, but that hepatic artery flow was not 
altered at 1 MAC and decreased at 2 MAC of halothane. 
Gelman and Dillard (60) found halothane anaesthesia 
resulted in a 40% rise in hepatic oxygen supply from a 
pentobarbitone control value. In a study of the 
reciprocity of hepatic blood flow, that is portal vein 
and hepatic artery flows, Seyde and Longnecker (61) 
demonstrated that, in contrast to isoflurane and 
enflurane, halothane anaesthesia in the rat impaired 
this mechanism, as assessed by the ratio of hepatic 
arterial to portal venous flow.
b) Enflurane
Irestedt and Andreen (62) studied the effect of 1 MAC 
enflurane anaesthesia on hepatic blood flow, 
electromagnetically measured, in dogs and found „ 
decreases in hepatic arterial and portal venous flows to 
65-70% of control and no significant effect on hepatic 
oxygen uptake. They concluded that these changes were 
primarily due to cardiovascular depression and that
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splanchnic blood flow was well preserved. Hughes and 
colleagues (57) in their study of greyhounds found 
dose related decreases in hepatic arterial and portal 
blood flows down to a value of 44% of control at 3% 
enflurane anaesthesia. In contrast to halothane 
anaesthesia, hepatic arterial resistance decreased 
significantly with enflurane. Tranquilli and colleagues 
(58) in a study of swine found no change in hepatic 
arterial flow but a marked fall in splanchnic flow 
during anaesthesia with 4% enflurane. The percentage of 
cardiac output increased to 133% of control during 
anaesthesia. Seyde and Longnecker (61) found 
preservation of the reciprocity of flow in the hepatic 
artery and portal system in rats during enflurane 
anaesthesia.
c) Isoflurane
There are fewer studies of the effect of isoflurane 
anaesthesia on hepatic blood flow than with the other 
agents. Gelman and colleagues (59) using a microsphere 
technique in dogs described a dose related decrease in 
pre-portal flow but a dose independant increase in 
hepatic arterial flow during isoflurane anaesthesia at 
1 and 2 MAC. In a subsequent study, Gelman and Dillard 
(60) found 1 MAC isoflurane anaesthesia in the dog 
increased the hepatic oxygen supply by 70% when compared 
to pentobarbitone aneasthesia. As with enflurane,
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isoflurane anaesthesia appears to preserve the 
reciprocity of hepatic blood flow in rats (61). 
Isoflurane anaesthesia produced no change in hepatic 
arterial flow in pigs (63). Lam and colleagues (64) 
demonstrated preservation of hepatic blood flow, as 
estimated from indocyanine green clearance, in man 
durirfcf isoflurane induced hypotension. They also found 
that on recovery of normal blood pressure, but still 
during anaesthesia there was a significant fall in 
estimated hepatic blood flow.
d) Intravenous induction agents
The use of intravenous induction agents as the sole 
method of anaesthesia has not been studied but there are 
several studies where a combination of nitrous oxide and 
incremental doses of an induction agent have been used. 
The effect of nitrous oxide on hepatic blood flow has 
been studied in dogs by Thomson and colleagues (65), who 
found a dose related decrease in hepatic arterial and 
portal venous blood flow, reaching a maximum decrease of 
20% with 70% nitrous oxide. Levy and colleagues (66), 
using disappearance of radioactive colloid to estimate 
hepatic blood flow, found a decrease of nearly 40% 
during thiopentone infusion- nitrous oxide anaesthesia 
in spontaneously breathing patients. In the same study, 
a mean decrease of 15% was found during thiopentone- 
nitrous oxide- suxamethonium anaesthesia. Epstein and
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co-workers (67) found little change in estimated hepatic 
blood flow during nitrous oxide anaesthesia following 
thiopentone induction.
Using a dog model, Irestedt and Andreen (68) 
demonstrated a 25% fall in total hepatic blood flow 
during neurolept anaesthesia with droperidol,fentanyl 
and nitrous oxide.
e) Spinal anaesthesia
Mueller and colleagues (69), in a study of spinal 
anaesthesia using procaine, described a mean fall in 
hepatic blood flow of about 20% during low (T10) and a 
fall of 30% during high (T2-3) spinal anaesthesia. 
Kennedy and colleagues (70) found that lignocaine spinal 
anaesthesia to T5 level caused a 23% decrease in hepatic 
blood flow at 1/2 hour which had recovered to 90% of 
control at 1 hour.
1.4.3 Summary
Anaesthesia produces a decrease in hepatic blood 
flow. With the inhalational agents this change appears 
to be dose related. Halothane anaesthesia causes a dose 
related decrease in both hepatic arterial and portal 
venous flow and impairment of the reciprocity of the two 
flows. Enflurane anaesthesia appears to have less effect 
on arterial blood flow but at higher concentrations the 
total flow is lower than with halothane due primarily to
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the cardiovascular depressive effect of enflurane. There 
are fewer studies during isoflurane anaesthesia but it 
appears that reciprocity is maintained with an overall 
decrease in total hepatic blood flow but a relative 
increase in hepatic arterial flow. Decreases of 20-25% 
in total hepatic blood flow have been demonstrated 
during intravenous anaesthesia supplimented by nitrous 
oxide and during subarachnoid anaesthesia.
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1.5 Distribution of drugs in the body
The final mechanism by which the disposition of a 
drug may be altered is by change in its distribution 
within the body. This may occur by changes in the volume
of distribution of the drug or by changes in the extent
of protein binding, hence amount of free drug in the 
plasma.
1.5.1 Volume of distribution
The volume of distribution of drugs has been shown to 
be altered in disease states. A decrease in the volume
of distribution of lignocaine has been demonstrated in
patients with congestive cardiac failure, perhaps 
arising from poor tissue perfusion (71). The effect of 
renal or hepatic disease on the volume of distribution 
of neuromuscular blocking agents has been studied. In 
renal disease, no significant effect on the volume of 
distribution of d-tubocurarine (72) , pancuronium 
(73,74), atracurium (75,76) or vecuronium (77) has been 
demonstrated but Ramzan (78) found a significant 
increase with gallamine. In hepatic disease a less clear 
picture is found. With pancuronium Duvaldestin (79) and 
Westra (80) demonstrated a significant increase in 
volume of distribution in hepatic disease (cirrhosis,
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biliary obstruction) but Somogyi (81) found no change.
Westra (80) found no change in the distribution volume 
of gallamine but Ramzan (82) found a significant 
increase in patients with biliary obstruction. No 
significant changes have been demonstrated for 
atracurium (75) or vecuronium (83,84) in patients with 
hepatic disease.
The acute effect of inhalational or intravenous 
anaesthetic agents on the distribution of drugs has not 
been studied extensively (85,86). The apparent volume of 
distribution of antipyrine was shown to be unchanged in 
the postoperative period (87). The plasma volume and
extracellular fluid volume are decreased after operation 
and this may influence drug distribution during this 
period. The majority of studies of drug distribution in 
the presence of anaesthesia have found no significant or 
consistant change in the apparent volume of 
distribution.
1.5.2 Protein- binding
Many drugs are transported in the blood to their site
of action bound to plasma proteins. An equilibrium is 
formed between unbound drug and a reversible 
drug-protein complex and this relationship obeys the law 
of mass action. Therefore, a fall in the concentration 
of unbound drug results in dissociation of the
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drug-protein complex to maintain the unbound drug 
concentration. The pharmacological effects of a drug are 
produced by the unbound fraction which can cross 
biological membranes to reach the target organ or 
receptor much more readily and is also eliminated from 
the body more easily. Changes in the amount of unbound 
drug, the free fraction, can result in changes in the 
pharmacokinetics and in the pharmacological action of a 
drug. The majority of drugs are bound to plasma albumin, 
alpha-1 acid glycoprotein (AAG) or lipoproteins. Drugs 
may bind to more than one protein eg prednisolone which 
binds to albumin, AAG and transcortin (a lipoprotein). 
Changes in the plasma concentration of these proteins, 
by disease or physiological response, will alter the 
free fraction of a drug. This is discussed below. 
Anaesthesia may alter the protein binding of a drug by 
two mechanisms. Drugs used for anaesthesia, or their 
metabolites, may compete for protein binding sites and 
displace other drugs. Anaesthesia may influence the 
production of proteins, especially AAG, and thus alter 
the total drug binding capacity of the blood.
a) Competition
The displacement of one drug by another competing for 
the same binding site is characterised by the
interaction of phenytoin and warfarin. The introduction 
of phenytoin therapy to a patient already taking
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warfarin results in increased effect of the warfarin 
because of displacement from the binding site on plasma 
albumin (88). Albumin has at least three binding sites 
which have been identified with marker drugs. These 
sites are characterised by discrete binding of diazepam, 
digitoxin and warfarin. Some drugs are able to bind to 
more than one site, eg sodium valproate binds to both 
the diazepam and the warfarin site (89). Diazepam can be 
displaced from its binding site on albumin by other 
benzodiazepines, penicillin derivatives and oral 
hypoglycaemics (90).
The volatile anaesthetic agents can, at high 
concentration, cause structural changes in plasma 
proteins (91). This may alter the affinity of the 
protein - drug binding. In vitro studies have shown 
that enflurane, halothane and trifluoroacetic acid (a 
halothane metabolite) displace diazepam from albumin but 
do not affect the binding of propranolol or prazocin 
(92) . There is little information on the in vivo 
effect of anaesthetic agents on drug-protein binding. 
Sulphaphenazole may displace thiopentone from protein 
binding sites leading to an enhancement of effect (93). 
In vitro studies suggest that bupivacaine which is 
highly protein bound may be displaced from its binding 
site by diphenylhydantoin, quinidine, pethidine and 
desipramine (94) . If this were to apply in vivo toxic 
effects may be noted at normal dose ranges as
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bupivacaine has a low therapeutic ratio (95).
Bupivacaine displaces mepivicaine in vitro (96) 
suggesting an interaction between amide local
anaesthetics.
An in vivo effect of competitive binding is a
possible explanation of the increased induction dose
required with the emulsion formulation of propofol when 
compared with that using the Cremophor formulation (97). 
An increase in drug binding to liposomes was postulated.
b) Altered binding capacity
The effects of the altered drug binding capacity 
resulting from the decreased or abnormal plasma protein 
concentrations in patients with renal or hepatic disease 
are well known in anaesthesia and are of clinical 
significance. Significant elevations in free drug have 
been demonstrated in patients with renal disease for 
thiopentone (98) , etomidate (99), diazepam (100) , 
midazolam (101) and alfentanil (102), and in patients 
with liver disease for morphine, thiopentone (103,104) 
and diazepam (105). The marked elevation of AAG 
concentration seen in patients following trauma and 
thermal injury leads to increased d-tubocurarine binding 
and hence to an increased dose requirement in these 
patients (106).
The effects of anaesthesia on drug binding capacity
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have been described following acute but not chronic 
exposure. Acute exposure studies describe the changes 
found following anaesthesia and surgery and imply a 
single exposure to anaesthetic agents. Chronic exposure 
studies of drug metabolism have been conducted using 
anaesthetists and operating theatre personnel who are 
regularly exposed to low doses of anaesthetic agents in 
their working environment. However, these studies have 
used antipyrine, which undergoes minimal protein 
binding, as the model drug and binding changes were not 
studied.
The effect of surgery and anaesthesia on drug binding 
has been demonstrated in several studies. Fremstad and 
colleagues (107) found an increase in the percentage 
binding of quinidine immediately following surgery which 
persisted for several days. Feely (108) reported a 
similar increase in propranolol binding following 
thyroid surgery. These changes closely paralleled 
changes in the acute phase reactant proteins, in 
particular in alpha-1 acid glycoprotein which avidly 
binds both of these drugs. Alpha-1 acid glycoprotein 
levels have been shown to be elevated, with resultant 
alteration in drug binding, during chronic cannulation 
(109) and in chronic inflammatory disease (110,111).
A more rapid effect on drug binding has been 
demonstrated during the administration of heparin. Wood 
and colleagues (112) found an altered binding of
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propranolol during heparinisation for cardiopulmonary 
bypass. Alteration in the extent of binding of several 
benzodiazepines has been demonstrated in volunteers 
given heparin (113).
A human study which measured the plasma binding of 
propranolol and verapamil in a group of patients 
undergoing cardiac surgery found this was not altered by 
anaesthesia. The extent of plasma binding of both drugs 
was not altered by administration of diazepam, fentanyl 
or halothane but was altered by heparin and 
cardio-pulmonary bypass (114).
An in vitro study by Dale and Nilsen (92) found 
that at clinical concentrations enflurane increased the 
free fraction of diazepam by 60%. The halothane 
metabolite tri-fluroacetic acid (TFA) at a concentration 
found post-operatively increased the free fraction of 
diazepam by up to 90%. Halothane, TFA or enflurane did 
not significantly alter the binding of propranolol or 
prazocin.
1.5.3 Summary
There is little evidence that anaesthetic agents 
produce an acute change in the volume of distribution of 
other drugs. Competition with other drugs for drug 
binding sites on plasma proteins has been demonstrated 
for inhalational, intravenous and local analgesic
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agents. The unbound fraction of many drugs including 
anaesthetic agents is increased in patients with liver 
or renal disease. In the postoperative period the 
increase in phase reactant proteins may alter the extent 
of drug binding.
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2.1 Anatomy
2.1.1 Gross anatomy
The liver receives its blood supply from the hepatic 
artery and the portal vein. The hepatic artery arises 
from the coeliac artery and supplies 30 - 40% of the 
total hepatic blood flow. The portal vein is formed from 
the superior mesenteric and splenic (hence inferior 
mesenteric) veins. The hepatic artery and portal vein 
run together, undergoing serial branching accompanied by 
tributaries of the bile duct, throughout the liver. 
There is no communication between the right and left 
halves of the liver. The venous drainage is through the 
three (central, right and left) hepatic veins which join 
the inferior vena cava separately on the upper surface 
of the liver just below the diaphragm.
The biliary system is formed within the liver by the 
confluence of bile canaliculi into ductules which then 
form the bile ducts. These emerge from the liver as the 
right and left bile ducts and join to form the common 
hepatic duct. The cystic duct from the gallbladder joins 
the common hepatic duct to form the common bile duct 
which runs behind the duodenum and pancreas and opens
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into the second part of the duodenum, about 10cm from 
the pylorus, at the ampulla of Vater, usually in common 
with the pancreatic duct.
2.1.2 Microscopic anatomy
The microscopic anatomy of the liver is described 
classically using the hexagonal, lobular model. Modern
descriptions are derived from the structure of the 
hepatic microcirculation and define the hepatic acinus 
as the basic unit. An acinus is an irregular parenchymal 
mass surrounding a terminal portal vein and its
accompanying hepatic arteriole and bile ductule. The 
portal vein is the key structure of the hepatic
microcirculation. The portal vein undergoes successive 
subdivisions, accompanied by hepatic arterial branches, 
to terminal divisions 20 - 30pm in diameter which have 
very short side branches opening into the hepatic
sinusoids. The sinusoids are lined by endothelial and 
Kupffer cells and, from them, the blood perfuses the 
liver parenchyma and drains directly into a branch of 
the hepatic vein. Kupffer cells (phagocytic endocytes) 
are part of the reticulo-endothelial system. They play a 
role in bilirubin production and act as scavengers of 
the hepatic circulation, phagocytosing particulate 
matter such as damaged erythrocytes. Hepatocytes are
53
polygonal epithelial cells, approximately 3 0um in 
diameter, which form a single cell plate with one 
surface facing the sinusoidal space and the other facing 
the bile canaliculus. The sinusoidal surface is covered 
in microvilli related to the cell's secretory and 
absorptive activity. The canalicular surface has an 
uneven covering of microvilli.
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2.2 Hepatic blood flow
2.2.1 Total hepatic blood flow
The liver receives approximately one quarter of the 
cardiac output, resulting in a total hepatic blood flow 
of about 1500ml.min, that is over 1ml per gram of liver 
tissue per minute. The intrahepatic distribution of the 
hepatic artery and portal vein, and the hepatic 
microcirculation are described above. The hepatic artery 
normally contributes 30-40% of the total hepatic blood 
flow.
The total hepatic blood flow is determined by the 
perfusing pressure (arterial and portal venous pressure) 
and the resistance. The resistance to flow is 
determined by three factors : the hepatic arterial
resistance, the vascular resistance of the intestinal 
vessels, and the intrahepatic portal vascular 
resistance.
2.2.2 Hepatic arterial flow
The mean hepatic artery pressure is about lOOmmHg and 
the arterial bed demonstrates pressure-induced 
autoregulation. The hepatic arterial flow is subject to 
some degree of pressure-induced autoregulation
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(115-120). The degree of autoregulation is not of major 
physiological significance and the classic pressure-flow 
relationship of, for example, the coronary artery has 
not been demonstrated consistantly (115,117). It has 
been suggested that hepatic arterial autoregulation may 
be of greater importance when the liver is active 
metabolically than in the denervated preparation used 
for autoregulation studies (121,122).
2.2.3 Portal venous flow
The portal flow does not appear to have direct 
autoregulation, but is subject to an inflow control from 
the splanchnic circulation. Portal venous flow accounts 
for 60-70% of total hepatic flow. The pressure within 
the portal vein is about 200 mmH20, falling to 50 mmH20 
in the terminal portal veins. Most studies have 
demonstrated a linear relationship between pressure and 
flow for the portal system (123-128). The portal 
vascular resistance increases in the presence of low 
portal blood flow and decreases at very high flows. This 
supports the theory that the regulatory mechanism 
governing portal flow is the maintenance of portal 
venous pressure. This theory is attractive in that the 
input into the portal vein can be varied by alterations 
in the splanchnic blood flow and that the portal vein 
serves to provide a constant perfusing pressure for the
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sinusoids.
2.2.4 Reciprocity
A reciprocity between hepatic arterial and portal 
venous blood flow has been demonstrated in man 
(129-133). For example, the reduction of portal flow 
during haemorrhage is compensated for, in part, by an 
increase in hepatic arterial flow. This
inter-relationship is inadequate to compensate for 
complete obstruction of one of the flows. It is possible
that the portal flow may be governed by changes
occurring in the hepatic arterial flow in response to
the metabolic oxygen demands of the liver.
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2.3 Regulation of hepatic blood flow
The regulation of flow through the liver is subject 
to metabolic, neuronal and hormonal factors.
2.3.1 Metabolic control
The increase in the metabolic activity of the liver 
which occurs after eating results in an increase in the 
total hepatic blood flow (134,135). This is due to, in 
part, the increase in splanchnic blood flow producing an 
increase in portal flow (135,136), and in part to an
increase in hepatic arterial flow (134). A similar
pattern is seen during enzyme induction (137,138). Both 
of these changes are accompanied by an increase in both 
portal and arterial oxygen extraction. The stimulus to 
the increase in flow may be a local metabolic change 
resulting from the increased oxygen demand. The effect
of alterations in arterial and portal oxygen and carbon
dioxide tensions has been described in animal studies. 
In the dog an arterial p02 of 5.8kPa had no detectable 
effect on arterial or portal flow, but severe hypoxia 
(pa02 3.3kPa) produced a decrease in hepatic arterial
flow and an increase in hepatic arterial resistance 
(139,140). An increase in portal venous oxygen content 
caused an increase in hepatic arterial resistance (13 0)
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but an arterial p02 of 53kPa had no effect on hepatic 
blood flow (140). Also in the dog, a moderate increase 
in arterial pC02 (8.6kPa) produced a small rise in 
arterial and larger rise in portal venous blood flow 
(139) . A similar effect on flow was seen with 
hypercapnia and acidosis (pH 6.8) (129). Hypocapnia and
alkalosis cause a fall in arterial and portal flow 
(129,139). Decreasing the pH of portal blood produced a 
marked increase in portal resistance and a smaller 
decrease in arterial resistance (130). It is likely that 
changes in the portal rather than systemic p02, pC02 and 
pH are a more important influence on hepatic blood flow.
2.3.2 Neuronal control
The hepatic vasculature is known to receive 
innervation from both the sympathetic and 
parasympathetic systems. It seems likely that 
stimulation of the vagus nerve has little effect on 
hepatic blood flow in the dog. It may be that vagal 
stimulation alters the microcirculation without 
affecting the overall flow. An increase in sinusoidal 
diameter during vagal stimulation has been.demonstrated 
in the rat (141). Stimulation of the sympathetic 
peri-arterial nerves, in the cat (142) or dog (143-145), 
causes arterial constriction, suggesting that this is an 
important regulator of hepatic vascular tone. The same
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frequencies of stimulation also cause an increase in 
portal pressure and portal vascular resistance in both 
the cat (142) and dog (144,145). Sympathetic stimulation 
also causes a slower, sustained contraction of the 
capacitance vessels within the liver with resultant 
decrease in hepatic volume (146). In this way the liver 
acts as a reservoir for blood which can be released into 
the ciculation in a controlled manner during periods of 
sympathetic stimulation. In the dog a maximum of 60% of 
the hepatic blood volume can be released (147).
2.3.3 Hormonal control
The hepatic and splanchnic vascular bed contains both 
alpha- and beta- adrenergic receptors.
Alpha-adrenoreceptor stimulation resulting from an 
infusion of noradrenaline reduces total hepatic blood 
flow by hepatic arterial and portal venous constriction 
in both the awake and anaesthetised dog (148-150). This 
effect is present during infusion of noradrenaline to 
therapeutic concentrations but such concentrations will 
not be reached by endogenous noradrenaline release. The 
effect can be blocked by alpha-adrenoreceptor 
antagonists (133). Beta-adrenoreceptor stimulation 
produces a hepatic arterial vasodilation but has no 
effect on portal vascular resistance which indicates an 
absence of beta-adenoreceptors in the portal vein
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(123,151,152,153). The effect of adrenaline at basal 
physiological concentrations is to cause hepatic
arterial vasodilation and increase splanchnic flow and, 
therefore, portal flow (154). An increase in adrenaline 
concentration would tend to increase hepatic blood flow, 
but this may well be accompanied by an increase in 
sympathetic nervous activity which has an arterial and 
venous constrictor effect (155). The resultant total 
effect will depend on the balance of these two 
mechanisms. The beta-adrenergic agonist isoprenaline has 
been shown to cause hepatic arterial vasodilation 
(120,123). This can be attenuated by beta-adrenergic 
blockade with propranolol (120,123). Propranolol does 
not affect the portal venous constrictor effect of 
noradrenaline (152) and intensifies the arterial 
constrictor effect of mixed alpha- and beta- adrenergic 
agonists such as adrenaline (133,156). Beta-adrenergic 
blockade with propranolol does not alter either hepatic 
arterial or portal venous resistance, but a transient 
increase in hepatic arterial resistance following
O.lmg/kg IV in the dog has been described (151). An 
overall reduction in hepatic blood flow of 10-20% has 
been described during beta-adrenergic blockade, due 
mainly to the decrease in cardiac output.
2.3.4 Other factors
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Hepatic blood flow is increased after eating and this 
is due to increased flow in both the hepatic arterial 
and the splanchnic (portal) systems. Several mechanisms 
appear to be responsible for this postprandial 
hyperaemia, including : increased osmolarity of the
portal venous blood (157), bile acids and salts (158) 
and a number of gastrointestinal hormones (159). None of 
the hormones administered alone exerts sufficient effect 
on hepatic blood flow to be considered a regulator of 
flow but in combination they probably produce the 
hepatic arterial vasodilation seen after eating (160). 
Glucagon causes hepatic arterial dilation and 
antagonises hepatic arterial vasoconstriction (161-163). 
It is likely that these properties are of importance 
when glucagon is released during stress in that they 
will maintain hepatic arterial flow to meet the 
increased oxygen demands of glycogenolysis (164).
The splanchnic circulation, hence the portal flow, is 
influenced by respiration, intra-abdominal pressure, 
gravity and by gut wall activity. During exercise there 
is a marked decrease in portal flow due to splanchnic 
vasoconstriction.
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2.4 Measurement of hepatic blood flow
2.4.1 Techniques
The techniques for measurement of hepatic blood flow 
can be classified broadly into direct and indirect 
methods.
The direct methods are, in general, more invasive and 
include the application of electromagnetic flow probes 
and heat exchange thermocouples. They have been 
implanted both acutely and chronically in animal 
preparations to measure separately both portal and 
arterial flow. The use of such probes in humans is 
limited to the acute intra-operative situation, such as 
during abdominal surgery. The indirect methods have been 
applied to clinical research more widely and a fuller 
description of the indirect methods will be given.
2.4.2 Indirect measurement
The indirect methods of measuring hepatic blood flow 
have the advantage of being less invasive but the 
majority produce only an estimate of total hepatic blood 
flow. A further disadvantage of these methods is the 
inability to j differentiate between the portal and
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arterial flows. These techniques are dependent on
removal of a marker substance from the blood by the 
liver. The most commonly used is the clearance method 
which is based on the Fick principle and hepatic blood 
flow is taken as the inverse of the arterio-venous
difference in concentration across the liver.
2.4.3 Clearance and hepatic blood flow
Estimation of hepatic blood flow has been made by 
relating the rate of extraction or clearance of a 
substance from the blood by the liver to the blood flow 
through the liver. Such calculations are based on the 
Fick principle which states that, at steady state, the 
amount of a substance taken up by an organ is equal to 
the product of the arterio-venous difference in
concentration of the substance and the blood flow 
through the organ.
blood flow rate = amount removed/unit time
arterio-venous difference
a) Bromsulphthalein
The use of this principle to estimate hepatic blood 
flow was described in 1945 by Bradley and colleagues 
(165). They measured the removal of bromsulphthalein 
(BSP) by the liver during a constant rate infusion. 
Samples of arterial and hepatic vein blood were taken to
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measure a-v difference. It was assumed that the arterial 
concentration of BSP was constant and therefore that the 
rate of removal of BSP by the liver was equal to the 
rate of infusion. Thus ;
H.B.F. = rate of infusion of BSP X 1
arterial - venous BSP cone. Haematocrit
As BSP is cleared only from the plasma this method 
actually measures hepatic plasma flow and correction 
using the haematocrit must be made to estimate hepatic 
blood flow.
This method makes several assumptions including : 
that the arterial concentration is constant, that only 
the liver removes BSP from the blood and that there is 
no enterohepatic circulation. In certain circumstances 
each of these may not hold true and may introduce error 
into the estimation.
The properties which are desirable in an indicator 
substance used for estimation of hepatic blood flow with 
this method include :
I. Rapid and complete mixing with the blood. This is of 
particular importance when the single injection 
technique is used as described below.
2. Removal from the blood only by the liver
3. No entero-hepatic circulation
4. A high rate of extraction from blood by the liver
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which follows a first-order, concentration independent 
process.
5. No systemic or toxic effects.
6. Small volume of injection relative to blood volume 
Bromsulphthalein does not fulfill all of these
criteria. A small amount ( <10%) of BSP undergoes
extrahepatic extraction and a small amount of 
enterohepatic circulation may occur (166). The
extraction of BSP can vary and may be less than 10% in
the presence of a raised serum bilirubin (167).
b) Indocyanine green —
The dye indocyanine green (ICG) is used more commonly 
for estimation of hepatic blood flow. ICG has a high
hepatic extraction ratio and is removed almost
exclusively by the liver. There is minimal enterohepatic 
circulation (168). Two different methods of 
administration have been used for ICG to determine 
hepatic blood flow (169). The method of continuous
infusion described for BSP has been used, but as this 
requires cannulation of the hepatic vein, a simpler, 
less invasive method has been devised. This involves
bolus injection into a central or peripheral vein and 
sampling from the systemic circulation. This technique
has been used to measure cardiac output and arterial 
sampling is required. However, for measurement of
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hepatic blood flow peripheral venous sampling is used 
usually (170).
Hepatic blood flow can then be estimated by 
calculating the total blood volume and the exponential 
rate of elimination (k) of ICG from the blood :
HBF = k x blood volume
An alternative method calculates the slope (K) of the 
plot of the log of plasma ICG concentration against time 
and the extrapolated zero time concentration (CpO) from 
this plot :
HBF = K. Dose of ICG X 1
CpO Haematocrit
This method which essentially calculates the plasma 
clearance of ICG which is considered to be equivalent to 
hepatic plasma flow. This value must then be corrected 
by the haematocrit to obtain blood flow. This method is 
described more fully in the Methods section. A
disadvantage of ICG is that is must be measured 
immediately as it is not stable at room temperature and 
deteriorates with time even when stored frozen (168).
The term clearance used in association with 
bromsulphthalein and indocyanine green is taken to
describe the efficacy with which the liver removes the 
substance from the blood and does not imply any
metabolic process. Both substances undergo two
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processes, uptake from plasma and excretion in the bile, 
which require normal hepatic function. BSP also 
undergoes conjugation before excretion. In patients with
hepatocellular damage or biliary obstruction the
clearance of both ICG and BSP may be impaired.
c) Other substances
A similar form of clearance measurement can be made 
using colloids which are taken up avidly by the Kupffer 
cells. This method, described originally in 1952 
(171,172), is based on the ability of Kupffer cells to
remove colloidal particles of a certain size on 
first-pass. Therefore, with an extraction ratio of 
virtually 100% the need for hepatic vein sampling is
avoided and the single injection technique described for 
ICG can be used. A number of radio-labelled substances 
such as P32 labelled chromic phosphate, 1131 labelled 
albumin and colloidal gold (Aul98) have been used to 
measure hepatic blood flow (172,173). The particle size 
is critical and false values may be obtained due to 
recirculation of small particles. This technique still 
.requires blood sampling for counting the disappearance 
of the radioactivity. An alternative version of this 
technique involves external counting over the forehead 
or calf (174,175). This has been found to have a similar 
rate of disappearance (k) of radioactivity. However as
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hepatic blood flow is equal to k times blood volume, 
blood volume must be calculated. The disadvantages of 
these methods include the expense and limitations on 
repeated measurement. The phagoctosing activity of 
Kupffer cells may be less affected by liver disease than 
hepatocyte activity and, therefore, a better estimate of 
flow may be obtained with this method in the presence of 
hepatic disease.
d) Metabolic clearance
The clearance of substances which require an hepatic 
enzymatic process for their elimination have been used 
to estimate hepatic blood flow. The use of this 
technique (176) is based on the venous equilibration 
model of hepatic drug clearance, which is described in 
Chapter 3. The clearance of a substance metabolised by 
the liver can be either enzyme or perfusion limited. An 
enzyme limited clearance occurs when a drug is of low 
hepatic extraction, that is, only a small amount of that 
presented to the liver is removed on each pass, and 
clearance is therefore independant of hepatic blood 
flow. Perfusion limited clearance occurs when the drug 
is removed in the liver by a process with a large 
reserve of enzyme of high affinity for the drug. This 
results in most of the drug being removed on a single 
pass through the liver and the rate of clearance being
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determined by the amount presented to the liver, that 
is, the hepatic blood flow.
The measurement of hepatic blood flow based on this 
concept compares the oral and intravenous administration 
of the same dose of a drug. The drug must be absorbed 
completely from the gut and metabolised only in the 
liver. The hepatic blood flow can be calculated from the 
dose of drug and the difference in area under the 
time-concentration curves for the oral and intravenous 
administration.
Hepatic blood flow = Dose
AUCiv - AUCo
The drug is given on two separate occasions, once 
orally and once intravenously. This technique has been 
described in man (177,178). However, its use has been 
limited by the assumptions required to apply this method 
which influence its accuracy. The most important of 
these are that all the drug is absorbed when given 
orally and that the basal conditions of hepatic blood
flow and enzyme activity are the same on the two study
periods.
e) Dual route administration
A more accurate development of this is the dual route
technique which is described in the Methods. This 
technique applies the the same model described above but
70
the drugs are administered simultaneously orally and 
intravenously (179). To differentiate between the two
routes one dose is radiolabelled. This allows a smaller 
dose to be given by the oral route than by the
intravenous which is appropriate for a drug of high 
first pass metabolism. Hepatic blood flow is then
calculated from the formula
HBF = DOSEo.DOSEiv
AUClv.Do - AUCo.Div
The derivation of this formula is given in the Methods.
2.4.4 Inert gas washout
As the name implies this technique measures the
elimination of an inert gas injected into the portal 
system. Radio-labelled gas,such as 85Krypton (180) or 
13 3Xenon (181), is injected into a tributary of the 
portal vein or into the hepatic artery and its passage 
through the liver (washout) recorded by a gamma camera 
placed externally over the liver (182). This method 
requires an operative procedure which limits its use in 
patients to those undergoing laparotomy or to animal 
studies. A less invasive form of this technique has been 
developed which involves inhalation of a trace dose of 
133Xenon in oxygen in a closed system to equilibration 
(183,184). This occurs rapidly ( <5min) due to the 
relative insolubility of xenon. A scintillation counter
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measures the radioactivity over the liver at 
equilibration and over a 15min washout period after the 
breathing system is removed. The calculation of blood 
flow from external scintillation counting is complex but 
values similar to those found with other methods have 
been produced.
2.4.5 Fractional distribution
This method relies on the distribution of a centrally 
injected substance by the regional blood flow into
organs where it is taken up by the cells. Radiolabelled 
compounds such as 1131 antipyrine, 42KC1 and 86RbCl,
have been used (185). This technique is of use only in 
animal studies as the tissue has to be removed for
scintillation counting. A similar limitation is found 
with the use of radio-labelled microspheres (5-50um in 
diameter) which are injected centrally and become wedged 
in the capillaries of the target organ. This technique 
can be used for serial measurements by using spheres of 
different sizes and labelled with different isotopes 
(59,186).
2.4.6 Direct methods of measuring hepatic blood flow
Several methods of measuring flow have been described 
which are now only of historical interest. As implied by
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the title all these methods are invasive. The older 
techniques involve diversion of the blood flow through 
the measuring instrument, whereas the more modern 
techniques are applied to the vessel without interupting 
its continuity.
a) Diversion of flow
The simplest method was to divert the flow through a 
vessel into a graduated cylinder for a fixed time 
period. The flow, however, would be influenced by the 
change in circulating volume. More sophisticated 
instruments, such as the Ludwig stromuhr or liquid 
rotameters, returned the measured blood flow to the 
circulation. The Ludwig stromuhr involves a system of 
four tubes diverting blood from a vessel to a measuring 
chamber and returning it to the vessel. By clamping two 
of the tubes blood can be diverted in either direction 
through an oil filled calibrated chamber and flow 
calculated from volume per unit time. The liquid 
rotameter works on the same principle as the gas 
rotameters on anaesthetic machines with displacement of 
a bobbin in a tube which is compensated for variations 
in flow and viscosity. The use of a rotating vane inside 
a tube inserted into a blood vessel has been described.
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b) Electromagnetic flow probe
The technique most commonly used for direct 
measurement of hepatic blood flow is an electromagnetic 
flow meter. These instruments are based on the principle 
of measuring the induced electromagnetic field created 
when blood flows at right-angles to a magnetic field 
(187) . The voltage induced by the blood flow is 
proportional to its average cross-sectional velocity. 
The probe used to measure flow through larger vessels, 
such as the hepatic artery or portal vein, is C-shaped. 
This design allows the probe to wrap round the vessel 
creating a uniform magnetic field of constant 
cross-sectional area and maintains the vessel diameter. 
This instrument has been used in man most frequently 
during porto-caval shunt procedures to assess the extent 
and direction of flow (188). In animal studies such 
probes have been used both acutely and chronically 
implanted (189,190). The problems encountered include 
stability of baseline values and calibration.
c) Ultrasonic probes
Ultrasonic blood flowmeters utilise the distorting 
effect of a moving liquid on soundwaves of high frequency 
and very short wavelength. Two basic designs are used. 
The first uses two transducers placed on either side of
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the vessel such that the line connecting them forms a 
small acute angle with the direction of blood flow. Both 
transducers act alterately as transmitter and receiver 
the direction changing several hundred times a second. 
The velocity of the soundwaves travelling with the 
direction of blood flow will be higher than that of 
those travelling upstream. The difference between the 
two can be used to measure the velocity of the blood 
flow. The second method uses the principle of the 
Doppler phase shift. A transmitter and receiver are 
placed beside each other outside a vessel angled against 
the direction of flow. The small change in frequency 
from the transmitted to the received sound caused by 
reflection by the moving blood is detected by the 
receiver. This change is proportional to the velocity of 
the blood flow. It can be seen that both these methods 
measure velocity of flow rather than flow but flow can 
be calculated if the cross-sectional area and velocity 
profile are known. Despite this disadvantage these 
instruments have proved useful and can be made small 
enough to fit in a catheter tip.
d) Heat exchange
Heat exchange methods relate the loss of heat of a 
heated element to the rate of blood flow (191) . The 
simplest method involves a heated thermocouple placed in
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the vessel and the rate of heat loss measured. This, 
however, only measures change in flow rather than 
quantitative flow. A more sophisticated development 
places two thermistors in a catheter tip, one heated, 
one not and the difference in temperature over a time 
period gives a measure of heat clearance which is 
related to blood flow (192). These techniques have been 
used acutely in man (193) and also as chronic implants 
in animal studies (194).
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3.1 Introduction
The liver is the principal site of drug metabolism in 
the body. The primary mechanism is the biotransformation 
of lipid soluble compounds into more water soluble ones 
which are more easily excreted in the bile or by the 
kidneys. The resultant compound may be a smaller
fragment of the original molecule or a new larger 
molecular weight compound is formed by linkage 
(conjugation) of all or part of the original molecule 
with another produced in the liver. In general,
metabolites with a molecular weight of 500-1000 are 
predominantly excreted by the liver and the smaller ones 
are excreted renally. The hepatic drug metabolising 
enzymes are found mainly in the smooth endoplasmic 
reticulum of the hepatocyte, but are present also in the 
mitochondria and the cytoplasm.
The basic reactions involved in the hepatic
metabolism of drugs are oxidation (loss of electrons),
reduction (gain of electrons), hydrolysis (addition of 
an -OH group)and conjugation (linkage with another 
compound). These reactions can be divided into Phase I 
(oxidation, reduction and hydrolysis) and Phase II 
(conjugation) reactions. For many drugs the metabolite 
of an initial Phase I reaction undergoes a subsequent 
Phase II reaction before excretion.
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3.2 Drug metabolism reactions
3.2.1 Phase I reactions
Oxidation reactions
Oxidation of drugs by the liver is carried out by a 
series of enzymes found in hepatic microsomes known as 
the mixed function oxidases or cytochrome P-450 system. 
These enzymes are haemoproteins and contain an iron 
molecule which is able to accept and donate electrons to 
catalyse reactions. Oxidation reactions add an oxygen 
atom to the substrate and this in some cases results in 
cleavage of the molecule. A variety of reactions 
involving the P-450 system come under the general 
heading of oxidations and these are summarised below, 
with examples relevant to anaesthesia (195). These 
reactions include ? aliphatic hydroxylation
(thiopentone), aromatic hydroxylation (fentanyl), 
O-dealkylation (pancuronium), N-dealkylation (morphine), 
N-oxidation (pethidine), desulphuration (thiopentone) 
and dehalogenation (halothane).
Reductive reactions
Reductive reactions are much less common and include 
the metabolism of azo- (fazadinium) and nitro- 
(nitrazepam) groups to their corresponding amines. The
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dehalogenation of halothane to trifluoroethane is a 
reductive process which is normally a minor pathway of 
metabolism but may important in the development of 
halothane hepatotoxicity.
Hydrolysis
Hydrolysis of esters and amides occurs in most 
tissues including the liver. Esterases and amidases are 
involved in the metabolism of an number of drugs use*/in 
anaesthesia, including amide and ester local 
anaesthetics, atropine and pethidine.
3.2.2 Phase II reactions
Phase II reactions are essentially synthetic and 
involve the conjugation of a drug, or drug metabolite 
produced by a Phase I reaction, to form an inactive, 
polarised, water soluble compound for excretion. The 
substrates commonly involved include glucuronic acid, 
sulphates, acetyl groups (acetylation), amino acids (eg. 
glycine) and methyl groups (N-methylation). The 
oxidative metabolite of thiopentone, thiopentone 
carboxylic acid, is conjugated with glucuronide and 
excreted in the urine.
3.2.3 P450 enzyme system
The cytochrome P-450 system or mixed function
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oxidases are located in the hepatic smooth endoplasmic 
reticulum. They are pigmented haemoproteins which are 
involved in the metabolism of numerous endogenous and 
exogenous substances. The name P-450 derives from the 
observation that in a reducing environment (carbon 
monoxide) a microsomal suspension of the pigmented 
haemoproteins bound the carbon monoxide reversibly to 
exhibit a broad light absorption band with maximal 
intensity at the wavelength 450nm (196,197). This
pigment (cytochrome) is the final stage in a series of 
catalytic steps ~~and is involved directly in binding of 
the drug substrate and oxygen to microsomes. The mixed 
function oxidase system comprises of Cytochrome P450, 
the enzyme NADPH- cytochrome P450 reductase and a lipid 
component. The system is based on the ability of the 
iron in the haem molecule of cytochrome P450 to undergo 
cyclical oxidation-reduction reactions in conjugation 
with substrate binding and oxygen activation (198,199). 
The NADPH- cytochrome P450 reductase acts as the link 
between the NADPH-dependant electron transfer system, 
which involves several flavoproteins,. and cytochrome 
P-450 - substrate complex (Figure 1). The enzyme acts as
a carrier of an electron which it donates to the 
cytochrome-substrate allowing it to combine with an 
oxygen molecule (200). It is likely that a complex 
involving cytochrome P-450, oxygen and drug substrate is 
formed before one atom of the oxygen is incorporated
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into the substrate and the other reduced to water with 
the addition of a further electron from the NADPH 
system. The product of the substrate-oxygen reaction, 
the drug metabolite, is then released and the reduced 
cytochrome P450 combines with another substrate 
molecule. Using radiolabelled oxygen, it has been shown 
that the oxygen used in this cycle is derived from air 
and not from water (201). The function of the lipid 
component is not fully known but it has been shown to be 
essential for the system's activity. It may have a role 
in substrate binding, facilitation of electron transfer 
or act as a template for the complex formation of the 
other molecules.
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3.3 Models of hepatic drug metabolism
The pharmacokinetics of hepatic drug elimination has 
been studied widely and mathematical models developed to 
describe the limiting factors involved in hepatic 
clearance (202,203). The models make a number of 
assumptions regarding the extent of binding of the drug 
and the characteristics of the enzymes involved in the 
elimination of the drug including the Vmax (the maximum 
rate of the enzymatic process) and Km (the 
enzyme-substrate dissociation constant). They also assume 
that there is complete mixing between the hepatic 
arterial and portal venous blood before it reaches the 
sinusoids (204,205), that only unbound drug crosses 
membranes and that there is no barrier to diffusion 
across the membrane (206). The two basic models 
developed are the venous equilibration model and the 
parallel tube model.
3.3.1 Venous equilibration model
The venous equilibration model is described also as 
the "well-stirred” model (176,202). This arises from the 
assumption by this model that the liver is a single 
compartment with uniform drug concentration. The model 
also makes the assumption that the concentration of
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unbound drug in the venous blood leaving the liver is 
the same as that to be found within the hepatocytes. 
That is, that during transition of the liver a state of 
equilibrium forms between the blood and the tissue. It 
assumes also that the rate of elimination of a drug by 
the liver is the product of the capacity of the liver to 
metabolise the drug times the unbound concentration of 
the drug in the liver.
The mathematic expression of this concept relates the 
hepatic blood flow (Q), the fraction of drug unbound in 
the blood (fu), the steady-state extraction ratio (E), 
the intrinsic clearance of the unbound drug by the liver 
(Clint) and the total drug clearance by the liver (Clh)
Clh = QE = Q.fu.Clint
Q + fu.Clint
Thus, when Clint has a large value in comparison to 
Q, hepatic clearance will be proportional to Q. However, 
if Clint is small in comparison to Q, hepatic clearance 
becomes independent of Q. This can be illustrated by 
substitution of arbitrary values into the equation : 
eg Q= 1000, Clint = 5000 Clh = 833
Q= 500, Clint = 5000 Clh = 455
Q= 1000, Clint = 2500 Clh = 714
where halving the blood flow almost halves the hepatic
clearance but halving the Clint only produces a 15% 
reduction. In contrast when Clint is small :
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Q = 1000, Clint = 100 Clh = 9 1
Q = 500, Clint = 100 Clh = 83
Q = 1000, Clint = 50 Clh = 47
the effect is reversed.
It follows from this that when the liver has a large 
capacity to metabolise a drug (ie the drug is of high 
hepatic extraction) the rate of elimination will be
determined by the rate of presentation of the drug to 
the liver (ie the hepatic blood flow). The clearance of 
such a drug is described as perfusion limited. If the 
liver has a low metabolic capacity for a drug, low 
hepatic extraction, the rate of presentation of the drug 
will be less important and the determining factor will 
be enzymatic metabolic clearance rate. In this case the 
clearance of the drug is capacity limited.
3.3.2 Parallel tube model
The parallel tube model makes the same basic 
assumptions as the venous equilibration model but 
incorperates two additional ones (203). Firstly that the 
liver can be regarded as a group of parallel cylinders 
of the same length which have enzymes evenly distributed 
in all the cells surrounding each tube and that flow is 
in only one direction. The second assumption is that at 
any point along the length of the cylinder an 
equilibrium exists between drug in the cylinder and drug
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at the enzymatic site. If the parallel tubes can be 
equated to hepatic sinusoids this model would appear to 
be more accurate physiologically, as it takes account of 
a concentration gradient of the drug along the length of 
the tube. This introduces a non-linearity to the
solution of rate of removal of drug and therefore 
specific solution of velocity of removal, extraction 
ratio and clearance are not possible unless certain 
conditions are observed. If the concentration of unbound 
drug is less than the Km of any enzyme system and 
binding is not saturated by high drug concentrations a 
solution for the concentration of drug leaving the liver 
(Cout) can be derived ?
Cout = Cin.e -fbout.Clint,1/Q
where Cin is concentration of drug entering the liver, 
fbout is the unbound fraction of drug leaving the liver 
and Clint,1 is the maximal intrinsic clearance for the 
entire liver. Therefore :
Extraction ratio (E) = 1 - e -fbout.Clint,1/Q 
and as Cl =QE :
Hepatic clearance = Q.(1 - e -fbout.Clint,1/Q)
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3.3.3 Comparison of the models
The two models will produce very similar values for 
extraction ratio and clearance when describing the 
behaviour of drugs at the extremes of the range of 
extraction. That is a drug of high extraction clearance 
will be limited by hepatic blood flow and for a drug of 
very low extraction clearance will be limited by enzyme 
function (intrinsic clearance). The differences between 
the models are evident when describing drugs of 
intermediate clearance using the determinants of hepatic 
blood flow, drug binding and intrinsic clearance. 
Prediction of the effect of changes in hepatic blood 
flow on a range of hepatic extraction and clearance 
values provides a reasonable Correlation betwen the 
models with a maximal difference of 30% when the 
extraction ratio was between 0.7 and 0.8 (205). This 
agrees with an analysis of experimental data from a 
study of isolated perfused rat livers (207,208). There 
is reasonable agreement in predictions of 
bioavailability for most extraction ratios but when 
approaching unity (E=1.0) marked discrepancy occurs. 
There is very little difference in the predicted values 
for extraction or clearance with changes in unbound 
fraction for the entire range of extraction ratios. 
Changes in the intrinsic clearance produce a higher 
clearance using the venous equilibration model over the
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full range of extraction ratios and this effect is most 
evident at high extraction ratios.
Validation of these models under experimental 
conditions using isolated perfused livers has proved 
difficult. The venous equilibration model appears to be 
the more consistant with these studies when describing 
the behaviour of high extraction drugs, such as 
lignocaine (209).
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3.4 Hepatic drug elimination
The hepatic elimination of a drug can be influenced, 
theoretically, at a series of determinant steps in the 
process. These steps include ;
a) hepatic blood flow
b) the extent of binding of the drug to plasma proteins 
and blood cells
c) the uptake of the drug into the hepatocyte
d) the intracellular drug binding capacity ~
e) the rate and capacity of the enzymic reaction
f) the effect of the metabolite on the enzyme
g) the elimination of the metabolite into the bile or 
blood
Steps c - f can be considered under the general 
heading of intrinsic clearance. The contribution of, and 
the effect of changes in, these four factors, hepatic 
blood flow, drug binding, intrinsic clearance and
metabolites, on the elimination of drugs is discussed 
below.
3.4.1 Hepatic blood flow
The effect of changes in hepatic blood flow on drug 
elimination have been outlined above in the description 
of the venous equilibration model. The importance will
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depend on the route of administration of the drug and 
the extent of hepatic extraction. The clearance of a 
drug of high hepatic extraction given intravenously is 
proportional to hepatic blood flow (ie it is perfusion 
limited) and therefore, alterations in flow will produce 
a change in clearance (210). There would be no change in 
the clearance of an orally administered high extraction 
drug but the bioavailability would alter (Cliv = Clo x 
F). For drugs of low hepatic extraction the hepatic 
blood flow has little influence on the rate of 
elimination after either oral or intravenous 
administration (176). The inter-relationship between 
these variables can be illustrated by computer 
simulations which predict the effect on clearance or 
extraction ratio of changes in hepatic blood flow 
(Figure 2).
3.4.2 Drug binding
Within the blood a drug exists in two forms, unbound 
and bound. The drug is bound reversibly to plasma 
proteins and lipoproteins and to blood cells. The amount 
of unbound drug (free drug) is the principal determinant 
of drug efficacy. The free drug is available to cross 
membranes and reach receptor sites. An equilibrium forms 
across a membrane between the free drug concentrations 
on either side of the membrane and is independent of the
91
He
pa
ti
c 
cl
ea
ra
nc
e 
(l
.m
in
 
) 
ltd
 
Ex
tr
ac
ti
on
 
R
a
t
i
o
Figure 2
Effect of change hepatic blood flow on 
A) extraction ratio and B) hepatic clearance
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bound concentration. That is, if there is a difference 
in extent of binding on either side of a membrane the 
total amount of drug on each side will be different but 
the free concentration will be the same. If a drug is 
highly bound ( >90%) small changes in the extent of
binding will have a marked effect on the amount of free 
drug, and therefore, on its biological effect. However, 
a drug which has a low extent of binding will show only
a small change in free drug concentration in response to
a small change in binding.
The effect of drug binding on hepatic elimination
depends on the extent of hepatic extraction of the drug. 
A high hepatic extraction drug, such as propranolol 
(E=0.8), may be highly protein bound (propranolol 10% 
free). This suggests that on a passage through the liver 
both free and bound propranolol are taken up from the 
blood. The affinity for binding the drug for the 
proteins in the hepatocyte must be greater than its 
affinity for the plasma proteins. The clearance of
propranolol is not limited by protein binding (211). A 
decrease in plasma protein binding will tend to increase 
the volume of distribution and increase the half-life of 
a high extraction drug which is also lipid soluble (ie 
has a large volume of distribution) (176,212). Little 
effect is noted on either volume of distribution or 
half-life of a high extraction drug with a small volume 
of distribution. For a drug of low hepatic extraction
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such as warfarin, the free fraction will be larger than 
the extraction ratio. Therefore the rate of clearance 
will be limited by the extent of protein binding, ie the 
clearance will increase as the free fraction increases 
(213). A low extraction drug of small volume of 
distribution will not change volume but may decrease its 
half-life with a decrease in protein binding. If the 
volume of distribution is large it will tend to increase 
but no change will be seen in half-life.
3.4.3 Intrinsic clearance
The intrinsic clearance has been defined as the 
maximal ability of the liver to remove drug irreversibly
by all pathways in the absence of any flow limitations.
This term covers the uptake of a drug into the 
hepatocyte, its transport in the cell, the enzymatic 
metabolic process and the effect of metabolites. One of 
these steps will be the rate limiting step of intrinsic 
clearance. Uptake of a drug into the cell may be an 
active process as for many organic compounds (214) or a 
passive process with the drug moving down a
concentration gradient across the cell membrane. Lipid 
soluble drugs will traverse the membrane more easily.
The gradient across the membrane is maintained by the 
efficient and rapid binding of the drug by intracellular 
proteins, and also by the rapid formation of
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enzyme-substrate complexes. The intracellular binding of 
a drug could be the rate limiting step in the process if 
there was a higher affinity for the substrate with the 
intravascular proteins than with the intracellular ones, 
or if the capacity of the intracellular proteins was 
saturated easily (214).
The kinetics of the drug metabolising enzymes will be 
the major influence on drug elimination. The velocity of 
an enzymic reaction will be determined by the amount of 
enzyme available, the amount of substrate present and 
the action of any inhibitory or acceleratory mechanisms 
(215). The general formula for an enzyme substrate 
reaction is ?
E + S => ES => E + M
where E is the concentration of enzyme present, S is the 
concentrtion of substrate, ES is the enzyme-substrate 
complex and M is the metabolic product of the reaction. 
The formation of ES is a rapid process but its breakdown 
is much slower and an equilibrium is formed between ES 
and E and S. The relationship between the velocity of 
reaction (v) and substrate concentration describes a 
hyperbolic curve. This is the basis of the 
Michaelis-Menten equation;
v = Vmax.Km
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where v is the velocity of the reaction, Vmax is the 
maximum velocity of reaction when the enzyme is 
saturated with substrate and Km is the enzyme-substrate 
dissociation constant. Km describes the relationship 
between enzyme, substrate and enzyme-substrate complex 
concentrations ;
Km = (E - ES).S 
ES
Km can be determined using a Lineweaver-Burk plot which 
plots the reciprocal of v against the the reciprocal of 
S. The intersection of this line with the abscissa is 
-1/Km and the intercept with the ordinate is -1/Vmax.
It is likely that some drugs may be metabolised by 
more than one enzyme or that two drugs may compete for 
the same enzyme. In these situations the determination 
of Km is more complicated. The former case is likely to 
occur with drugs which undergo a simple oxidation with 
the P450 system.
The velocity of enzyme reaction can be enhanced or 
inhibited. This is different from enzyme induction or 
inhibition where the main change is in the concentration 
of enzyme available rather than a change in activity. 
The changes in velocity are usually related to the 
substrate concentration (215). High levels of substrate
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may inhibit the reaction by several mechanisms including 
binding of co-factors of the reaction, binding to 
inactive sites on the enzyme which interfere with 
binding to the active site or by outstripping the supply 
of other reactants required for the reaction. The 
velocity of reaction may be enhanced by binding at sites 
on the enzyme other than the active one. Such binding 
may cause a steric change which increases the binding 
capacity of the enzyme.
The reactions involving the hepatic drug metabolising 
enzymes proceed at a slow rate relative to many 
biological enzymatic processes eg. cholinesterases. To 
compensate for this the enzyme systems are able to speed 
up turnover by increasing their concentration, that is 
by induction. There are a large number of substances, 
drugs and chemicals, which are known to produce enzyme 
induction including barbiturates (216,217), ethanol 
(218,219) and cigarette smoke (220). Increase in enzyme 
activity will be noticed within 3-4 days of starting an 
inducing drug, reaching a maximum at 2 weeks, and will 
still be evident 2 weeks after discontinuation of the 
drug. The range of induced P450 enzymes will vary 
depending on the inducing drug. For example, a 
generalised inducion of many P450 forms will occur with 
phenobarbitone treatment (217), but a smaller range will 
be found with ethanol (219). Enzyme induction will 
result in a more rapid metabolism of drugs. Inhibition
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of P450 enzymes has also been described and results in a 
slowing of elimination and prolongation of effect of a 
drug. Drugs shown to cause inhibition include cimetidine 
(221), chloramphenicol (222) and allopurinol (223). The 
effect of anaesthetic agents on enzymes has been 
discussed in Chapter 1. The effects of hepatic drug
metabolising enzyme inhibition and induction will be 
most marked on drugs of low hepatic extraction.
Assessment of the activity of the hepatic drug 
metabolising enzymes is discussed later in the chapter 
(3.5).
It is possible for a metabolite of an enzymic process 
to interfere with the ongoing reaction which produces 
the metabolite. This may occur due to the metabolite 
binding on or near the active site of the enzyme, or as 
a chemical effect of the metabolite altering the
environment of the reaction.
3.4.4 Elimination of the metabolite
The end product of drug metabolism is a more polar 
water-soluble molecule. This molecule or conjugate is 
excreted from the hepatocyte into the biliary or hepatic 
venous system. The metabolites released into the 
systemic circulation are excreted usually by the kidney. 
The excretion of metabolites from the hepatocyte may be 
a passive process but active transport systems have been
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identified (224) . It is not normally a rate-limiting 
step in the elimination of a drug. Obstruction of the 
biliary outflow could, in a manner parallel to that seen 
in bilirubin metabolism, lead to an intracellular 
accumulation of metabolite or spillage of a metabolite 
normally excreted in bile into the the systemic 
circulation. Defective uptake of drugs by hepatocytes 
has been demonstrated in experimentally produced 
cholestasis (225).
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3.5 Assessment of hepatic enzyme activity
3.5.1 Introduction
The central role of the liver in drug metabolism 
makes it desirable to know the influence of hepatic 
enzymes on the elimination of a drug. This can be 
achieved by pharmacokinetic studies of the drug's 
elimination. In addition, it is desirable to evaluate 
the effect of a drug on the hepatic enzymes. This is 
achieved by measuring the effect of the drug on the 
pharmacokinetics of known substrates. The use of such 
model substrates can be extended usefully to measure the 
capacity and capabilities of the hepatic drug 
metabolising enzyme system. Such an approach has been 
used in the study of drugs which produce enzyme 
inhibition or induction and in the study of the genetic 
polymorphism of drug metabolism.
The properties of an ideal drug for use as a model 
for assessing hepatic enzyme activity would include 
(226) ?
a) single compartment kinetics allowing calculation of 
clearance from the elimination half-life.
b) elimination exclusively by hepatic metabolism
c) hepatic metabolism should be independent of hepatic 
blood flow and protein binding.
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d) if given orally the drug should be rapidly and 
completely absorbed
Additional information about the drug metabolising 
enzymes can be obtained if the metabolite or metabolites 
of the drug can be measured in plasma or urine. This may 
allow the differentiation of effects on alternative 
pathways of metabolism to be evaluated. However, the 
rate of production of the metabolite and its rate of 
excretion may differ (227).
A number of drugs have been used to evaluate hepatic 
drug metabolising activity, but none has been shown to 
fulfill the criteria set out above completely. The drugs 
used include those of low hepatic extraction such as 
antipyrine, aminopyrine and diazepam, and high hepatic 
extraction drugs such as propranolol, galactose, 
pentazocine and lignocaine. The use of low extraction 
drugs has the advantage that their elimination is 
independent of hepatic blood flow. However, simultaneous 
administration of a low and a high extraction drug has 
shown a correlation between the clearance of both drugs 
in patients with hepatic disease. The most commonly used 
drugs, antipyrine and aminopyrine will be described. 
Their use and the advantages and disadvantages will be 
discussed.
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3.5.2 Antipyrine
Antipyrine is a phenylpyrazolone derivative which 
has analgesic and antipyretic properties. Its mode of 
action is similar to that of the salicylates. Antipyrine 
has been used widely as a measure of hepatic enzyme 
activity because its metabolic profile is well suited to 
this task : ±t is well absorbed from the intestine after 
oral administration, its binding to tissues and proteins 
is limited, it has a low hepatic extraction ratio and 
therefore its elimination is independent of hepatic 
blood flow, almost all metabolism of the drug occurs in 
the liver and there is minimal ( <5%) renal excretion
(228). As it has single compartment kinetics both the 
plasma half-life and the clearance give a measure of 
hepatic metabolism (229). It has a relatively long 
half-life in man (8-14 hours) and, as the salivary 
concentration and plasma concentration are very similar, 
the former method of sampling has been found convenient. 
The long half-life is also a disadvantange which
precludes its use in sequential studies, as several days 
washout is required.
The metabolism of antipyrine involves the production, 
by the P450 system, of three oxidative metabolites. Its 
metabolism has been used, therefore, to assess the 
effect of liver disease on drug oxidation reactions
(230) and to assess the enzyme inhibitory or inductive
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effects of a wide range of drugs, including 
anticonvulsant (231) and antitubercular drugs (232) 
(inducers) and beta-adrenergic (233) and H2 blockers 
(234) (inhibitors) and factors such as smoking and 
eating (235,236). Attempts have been made to use 
antipyrine metabolism as a predictor of the ability of 
the liver to metabolise other drugs but the correlation 
has been variable (228). This may due to the relatively 
non-specific metabolic profile of antipyrine which 
involves at least three discrete mixed function 
oxidases. Some studies have attempted to parallel the 
production of an individual metabolite with a test drug. 
The half-life of antipyrine is increased in liver 
disease (237), hypothyroidism (238) and with age (239). 
Antipyrine may cause an induction of its own metabolism 
(240) and this, also, prevents its use in serial studies 
over a short time period.
3.5.3 Aminopyrine
Aminopyrine is also a pyrazolone derivative and is 
related to antipyrine. It has a shorter half-life than 
antipyrine and undergoes de-methylation by the hepatic 
microsomal enzymes. The products of its metabolism 
include formaldehyde, formic acid and C02. The last of 
these products has been used as an indirect measure of 
mixed function oxidase function. Administration of
102
aminopyrine radio-labelled with 14C allows measurement 
of its metabolism by detection of 14C02 in expired
breath (241). The expired C02 is adsorbed in collection 
vials for subsequent scintillation counting. The 
aminopyrine breath test has been used in animal and 
human studies to evaluate the effect of drugs (242) and 
environment on drug metabolism. This test also proved to 
be a poor predictor of the metabolism of other drugs 
such as diazepam (243). The main advantage of the 
aminopyrine breath test is that it is relatively simple 
to perform. A similar principle, measurement of the 
14C02 metabolite, has been applied to other
radio-labelled substances such as galactose (244), 
diazepam (222), mephenytoin (245) and caffeine (246).
3.5.4 Other drugs
Other drugs used as models of metabolising capability 
include theophylline which shows a variable response to
known enzyme inducers (247) and hexobarbitone (248) 
which has been used in many animal studies and has the 
advantage over amylobarbitone (249) of being metabolised 
almost entirely by hepatic microsomal enzymes.
3.5.5 Endogenous metabolites
The measurement of endogenous metabolic products has
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been' advocated as a measure of hepatic enzyme function. 
D-glucaric acid is the end-product of the glucuronic 
acid carbohydrate metabolic pathway and is excreted in 
the urine. An increase in the production of D-glucaric 
acid has been noted following known enzyme inducing 
drugs (250,251). However, the mechanism of this change 
is not fully understood and it may not represent enzyme 
induction. The urinary excretion of 6b-hydroxycortisol, 
a minor metabolite of cortisol produced by the hepatic 
mixed function oxidases, has been proposed as a measure 
of enzyme induction (252). I t  appears to be a reasonable 
measure of enzyme induction (240,253) but not of enzyme 
inhibition (253). As cortisol production is subject to 
many influences the production of 6b-hydroxycortisol 
does not correlate well with the clearance of test drugs 
and therefore, cannot be used as a predictor.
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3.6 Factors affecting hepatic drug metabolism
A number of physiological and environmental factors 
have been shown to influence the activity of hepatic 
drug metabolising enzymes.
Age
A large number of animal studies and human studies 
have demonstrated that with increasing age there is a 
decrease in the ability of the liver microsomes to 
metabolise drugs. Alterations in clearance and/or 
half-life have been demonstrated for many drugs in the 
elderly. These changes may be difficult to interpret as 
they are often accompanied by changes in drug binding 
and volumne of distribution. For example, diazepam 
half-life is prolonged in the elderly and the volume of 
distribution is increased (105). Antipyrine half-life is 
increased and clearance decreased suggesting that the 
metabolic activity of the liver decreases with age 
(239,254).
Sex
It might be expected from the difference in total 
body . water and fat that the distribution of a drug 
would differ between male and females. This, however, 
does not appear to be manifest in different rates of 
elimination of drugs. A higher rate of drug metabolism 
has been noted in male than in female rats, but this is
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the only species that this has been observed in. More 
effect might be expected with drugs dependent on renal 
elimination because of a lower glomerular filtration 
rate in females (255).
Species
Many studies of drug metabolism are done using an 
animal model initially. It is not possible to then 
extrapolate these results to any other species as the 
rate of of metabolism or pathway of metabolism may 
differ. There are many examples of these differences 
which can be illustrated by the different half-life of 
propranolol in dogs (lhr) and man (4hr) and the 
metabolism of sulphadimethoxine in rats (acetylation) 
and man (glucuronidation) (256). If the same metabolic 
pathway is present correction for body weight and 
circulation time (257) has demonstrated some correlation 
between body weight and oxidase activity in mammals 
(258).
Genetic
The inter-individual differences in response to a 
drug may be partly explained by the genetic variation 
within a study population. For many drugs the 
individuals' rate of drug metabolism would exhibit a 
normal distribution around a mean. For some drugs, 
however, a bimodal distribution may be found. The 
classic example of this is the acetylation of 
sulphadimadine which can discriminate between slow and
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fast "acetylators". The percentage of acetylated drug in 
the urine at 6 hours was used to determine the dose of 
isoniazid for antitubercular treatment (259). More 
recent studies have shown that there are genetic 
variations in drug oxidation capability. This has led 
to "oxidation phenotyping" using the hydroxylation of 
the antihypertensive debrisoquine (260,261) or the 
oxidation of alkaloid sparteine (262) as discriminants* 
An autosomal recessive characteristic of poor ability to 
hydroxylate debrisoquine has been demonstrated (260). 
This characteristic does not appear to be associated 
with changes in antipyrine kinetics (263,264) but 
several reports have linked poor metabolisers with an 
increase in adverse effects of drugs undergoing 
oxidative elimination such as beta-adrenergic blocking 
drugs (265,266).
Liver disease
It would be expected that the changes produced by 
liver disease would include a decrease in the ability of 
the hepatocytes to metabolise drugs. These changes may 
be difficult to demonstrate in isolation as concurrent 
changes in hepatic blood flow and drug binding capacity 
are likely to be present. The nature and severity of the 
disease and the pharmacology of the drug will be 
important. A review of 30 studies comparing the 
disposition of a number of drugs in patients with or 
without liver disease found altered kinetics in only 60%
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of the studies (267). Antipyrine elimination has been 
shown to be impaired more in patients with chronic liver 
disease than in patients with acute reversible liver 
disease (237). Studies with other drugs in various 
hepatic diseases such as hexobarbitone in acute hepatitis 
(268), pethidine in cirrhosis (269) and propranolol in 
chronic liver disease (270) have concluded that
impairment of elimination of a drug increases with the 
severity of the disease but correlates poorly with 
biochemical measures of severity.
Renal disease
The presence of renal disease should not affect 
directly the hepatic metabolism of drugs. There may be 
an alteration in the disposition of the drug due to 
changes in total body water and altered drug-protein 
binding. An increase in the adverse effects due to
accumulation of an active metabolite of an extensively 
metabolised drug, which is excreted by the kidney 
normally, might be expected.
Drug interactions
The ability of some drugs to influence the metabolism 
of other drugs has been recognised for many years. This 
interaction may accelerate or inhibit the rate of 
elimination. The increase in rate of metabolism of
warfarin caused by concurrent barbiturate 
administration, with a resultant decrease in
anticoagulant action, has been well documented. Drugs
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associated with an inductive effect on the metabolism of 
other drugs include the barbiturates (217), phenytoin 
(271), phenylbutazone (272), carbamazipine (273) and 
rifampicin (274). Ethanol ingestion has an acute effect 
of slowing drug metabolism but chronic ingestion has an 
inductive effect (219) . Cimetidine is known to inhibit 
the oxidative metabolism of many drugs (221). Elevation 
of plasma concentration of drug and increased
therapeutic effect following co-administration of
cimetidine has been demonstrated with beta-adrenergic 
blockers (275,276), theophylline (277), benzodiazepines 
(278), warfarin (234) and phenytoin (279). Other drugs 
associated with enzyme inhibition and therefore
prolongation of drug effect are chloramphenicol (222), 
sulphaphenazole (280), monoamine oxidase inhibitors 
(281) and allopurinol (223).
Smoking
Tobacco smoke contains several thousand chemicals 
some of which are known to affect drug metabolism. The 
importance of taking a full history of smoking habits in 
subjects taking part in pharmacokinetic studies has been 
highlighted (220). Smoking has been shown to increase 
the rate of elimination of several drugs including
antipyrine (239), theophylline (282) and pentazocine 
(220) but not to affect the metabolism of others such as 
diazepam (283), pethidine (284), phenytoin (285) and 
warfarin (286).
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Environmental chemicals
The effect of environmental exposure, usually 
industrial, to chemicals has been shown to alter drug 
metabolism. Occupational exposure to chlorinated organic 
insecticides such as DDT (287) and to polychlorinated 
biphenyls (PCBs) (288) has been shown to produce enzyme 
induction as shown by a decrease in the half-life of 
antipyrine. Ingestion of dietary chemicals can also 
alter drug metabolism. This has been demonstrated by the 
increased rate of phenacetin metabolism after a diet of 
charcoal broiled beef, which has a high content of 
polycyclic hydrocarbons, when compared with a normal 
diet (289) . A high protein - low carbohydrate diet 
caused a decrease in theophylline half-life and a low 
protein - high carbohydrate diet caused an increased 
half-life (290).
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4.1 Anaesthesia studies with a dog model
4.1.1 Introduction
The pharmacokinetics of many drugs have been noted to 
be altered in the peri-operative period. There are many 
interacting factors involved in these changes including 
the stress response to surgery, alterations in regional 
blood flow and the effect of anaesthetic agents.
Anaesthetic agents, both inhalational and 
intravenous, may alter drug pharmacokinetics by effects 
on any of the principle determinants of drug 
disposition. As discussed in the introduction, these are 
the distribution of a drug in the body, the hepatic 
blood flow and the drug metabolising enzyme activity. 
There is a growing amount of evidence that the 
inhalational anaesthetic agents, especially halothane, 
cause alterations in the peri-operative pharmacokinetics 
of several drugs but at present there is little data on 
the effect of intravenous anaesthetic agents.
4.1.2 Hepatic extraction and route of administration
As most drugs are metabolised by the liver, any 
effect on the disposition of a model drug by an 
anaesthetic agent is likely to be due to changes in
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hepatic drug clearance which will result from
alterations in hepatic blood flow and hepatic
drug-metabolising enzyme activity. The extent of this 
effect will depend on the degree of hepatic extraction 
of the model drug. The clearance of a drug of high
hepatic extraction when given intravenously will be 
determined by its rate of delivery to the liver ie. the 
hepatic blood flow, whereas the intravenous clearance of 
a drug of low hepatic extraction will be determined by
hepatic enzyme activity. The clearance of both high and
low hepatic extraction drugs when administered orally,
the oral or intrinsic clearance, reflects hepatic enzyme 
activity and is unaffected by changes in hepatic blood 
flow.
4.1.3 Dual-route administration
It can bee seen that there is a different prime
determinant of hepatic clearance for a drug of high 
hepatic extraction depending on its route of 
administration. When the drug is given orally, changes
in- clearance will reflect changes in metabolic enzyme 
activity and when given intravenously it will reflect 
changes in hepatic blood flow. Thus, by determining the 
disposition of a high extraction drug given both orally 
and intravenously it is possible to measure the 
intrinsic clearance (hepatic enzyme activity) and
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estimate the hepatic blood flow (see Chapter 2). The 
model drug must be metabolised only by the liver and 
absorbed fully from the intestinal tract when given
orally. This technique can be improved considerably by 
administering the drugs simultaneously ’. This removes 
the major problem of assuming that basal conditions are 
the same on two study days. The oral and intravenous 
doses of the drug are differentiated by the 
radio-labelling of one of the doses, usually the 
intravenous one. This technique has been developed using 
propranolol as the model drug (291,292). Propranolol is
a beta-adrenergic blocking drug which has a high hepatic 
extraction ratio ( >0.7) and is rapidly and completely
absorbed when given orally (293).
This technique of dual-route administration of
propranolol, simultaneous labelled intravenous and 
unlabelled oral administration, has been used previously 
to measure effects on drug disposition (294-296).
4.1.4 Aim of studies
The aim of these studies was to assess the effect of 
different anaesthetic techniques on drug disposition, in 
the dog, in the absence of other influences such as 
surgery. The technique of dual-route administration, 
with propranolol as the model drug, was used to 
determine the relative contributions of changes in
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hepatic blood flow and hepatic enzyme activity to any 
alteration in drug disposition during anesthesia.
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4.2 • Human study
4.2.1 Cimetidine
Cimetidine, a histamine H2 receptor antagonist, is 
used widely for the treatment and prophylaxis of gastric 
ulcers. The concurrent administration of cimetidine has 
been shown to alter the pharmacokinetics of a large 
number of drugs (221) . This usually has resulted in 
increased plasma concentrations of these drugs with the 
increased risk of unwanted side effects (234,297,298). 
This change has been attributed to a decrease in hepatic 
blood flow and an inhibition of hepatic enzymes (275). 
The decreased enzyme activity has been demonstrated in 
many studies and it is likely that cimetidine is an 
inhibitor of the cytochrome P450 enzymes (299,300). 
However, the effect of cimetidine on hepatic blood flow 
has not been demonstrated in all studies (300-303). The 
apparent decrease in hepatic blood flow demonstrated in 
some studies may be due an alteration in the extraction 
of the . indicator drug used to estimate blood flow 
produced by cimetidine.
4.2.2 Enprostil
Enprostil (RS-84135, 11a,15a-dihydroxy- 9-keto
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-16-phenoxy- 17,18,19,20-tetranorprosta- 4,5,13(t)- 
trienoic acid, methyl ester) , a research drug produced 
by Syntex, is a synthetic dehydro- prostaglandin E2. It 
has been shown to have effective anti-secretory and 
cytoprotective properties in animals. It is under 
investigation currently for the treatment of gastric and 
duodenal ulcers (304). The decrease in prostaglandin 
production caused by cyclo-oxygenase inhibitors such as 
aspirin or indomethacin leads to a decrease in basal 
gastric and intestinal blood flow (305-307). This 
suggests that splanchnic and thus hepatic blood flow is 
controlled at least partially by prostaglandins (308). 
It is thought that enprostil, therefore, may cause an 
increase in hepatic blood flow. It has been shown that, 
in vitro , prostaglandins affect the hepatic metabolism 
of several drugs including aminopyrine, benzopyrene and 
hexobarbitone (309,310).
4.2.3 Aim of study
The aim of this study was to compare the effects of 
cimetidine and the synthetic prostaglandin E2, 
enprostil, on hepatic blood flow and hepatic enzyme 
activity in man. Within the context of this series of 
studies it provides three further elements ;
1) the extension of the dual route technique to human 
subj ects,
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2) a validation of this technique with a known enzyme 
inhibitor and
3) a comparison of the hepatic blood flow measurement 
from this method with that of the more widely used 
indocyanine green method.
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Dog studies
5.1.1 Outline
This series of studies involved dual route 
administration of propranolol during anaesthesia to five 
groups of dogs. The groups studied were ;
Group 1 - control (no anaesthesia)
Group 2 - halothane anaesthesia
Group 3 - isoflurane anaesthesia
Group 4 - enflurane anaesthesia
Group 5 - fentanyl-atracurium anaesthesia
Cannulae were implanted in the portal vein, femoral 
vein and femoral artery of each dog five days before the 
study period.
In each group each dog was studied on three 
consecutive days ;
Day 1 - awake, 24 hours before anaesthesia 
Day 2 - during anaesthesia (Group 1 awake)
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Day 3 - awake, 24 hours after anaesthesia
The dual route administration involved simultaneous 
injection of unlabelled propranolol into the portal vein 
and tritium-labelled propranolol into the femoral vein.
Blood samples were taken over the 4 hour study period 
for assay of the plasma propranolol and tritiated 
propranolol concentrations.
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5.2 Preparation of study dogs
5.2.1 Surgery
Five days before the first study day each dog had 
cannulae placed in the femoral vein, femoral artery and 
portal vein. The dogs were anaesthetised with
pentobarbitone (30mg/kg), the trachea intubated and the 
lungs ventilated with air. The dog was placed supine and 
the abdomen and left side of the chest shaved and 
prepared with chlorhexidine solution. A short
mid-abdominal, midline incision was made and the spleen 
was brought forward. A silastic catheter was then 
introduced into a small branch of the splenic vein and 
advanced into the portal vein. The position of the 
catheter was checked manually before it was secured with 
a suture. The ideal position was taken as being a few 
centimetres past the junction of the splenic and 
mesenteric veins. The proximal end of the catheter was
then brought subcutaneously to the left chest wall, 
going through the peritoneum separate from the incision.
Initially, the arterial and venous cannulae were 
placed in the internal iliac vessels within the
peritoneal cavity and brought trans-peritoneally then
subcutaneously with the portal cannula to the left chest
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wall. However, two dogs prepared early in the series 
developed intraperitoneal haematoma and could not be 
studied. It was decided that it would be easier to 
detect any post-operative bleeding if the cannulae were 
placed in the femoral vessels through a groin incision. 
This would also minimise the intra-abdominal surgery and 
decrease the length of the incision. In all other dogs 
the femoral vessels were mobilised and cannulated
through an incision in the right groin. The cannulae 
were advanced some 15 centimetres into the vessels and 
secured with a suture. The proximal end was brought 
sub-cutaneously, without entering the peritoneum, to the 
left chest wall.
The three cannulae were brought out on the left chest 
wall and secured separately to the skin. The cannulae 
were flushed with heparinised saline and secured in a 
pouch on a canvas "jacket" placed round the chest over 
the forelimbs. This arrangement worked well during the 
first two studies but one dog bit through the pouch and 
damaged the cannulae. The cannulae were then put into a 
small metal box in the pouch. This was satisfactory for 
the next two studies but a dog again got access to the 
cannulae. For the final studies the cannulae were left 
in a loop subcutaneously until the first study day when 
they were brought out and placed in the box in the 
pouch. At the end of surgery the dog was allowed to 
breathe spontaneously and the trachea was extubated.
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5.2.2 Animal care
The dogs were housed in the Animal Care Center, 
Vanderbilt University Medical School, in individual 
kennels. All the dogs were fed daily with the same brand 
of tinned dog meat and biscuits. The dogs were fasted 
overnight before the first study day, but had free 
access to water. They were fed on completion of the 
study period on days 1 and 2 and again fasted overnight.
During the study period on Days 1 and 3 of the first 
two studies the dogs were in a restraining sling. For 
the subsequent studies they were in a small cage which 
allowed them to lie down.
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5.3 Anaesthesia
5.3.1 Induction
A standard induction routine was used in all the 
groups receiving anaesthesia. Anaesthesia was induced 
with thiopentone (6-8 mg/kg), the trachea intubated with 
an 8.0 cuffed endotracheal tube and the lungs ventilated 
using an Ohio 800 Ventilator. Ventilation was initially 
set at 10 ml/kg and adjusted in accordance with the 
end-tidal C02 as described below. Anaesthesia was
maintained with the volatile agent in oxygen. The 
concentration of inhalational agent was adjusted to 
twice minimum alveolar concentration (2 MAC). The MAC 
value for dogs for each agent was taken from published 
comparative data (311). In group 5, in addition to the 
fentanyl, anaesthesia was maintained with 66% nitrous 
oxide in oxygen.
Comparative MAC concentrations (%) in dogs and man (311)
dog man
Halothane 0.86 0.77
Isoflurane 1.28 1.15
Enflurane 2.1 1.68
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Maintenance
5.3.2 Group 2 Halothane
Following induction of anaesthesia the lungs were 
ventilated with halothane 2.0 MAC (1.72% for dogs) in 
oxygen. End tidal halothane concentrations were measured 
by gas chromatography. The chromatogram was calibrated 
on the morning of each study by injection of known 
prepared concentrations of halothane in the range 0-5%. 
End-tidal gas samples were aspirated into a 30ml glass 
syringe from a sealed port on the endotracheal tube.
This was done at 15 min intervals until a stable 2 MAC 
concentration was obtained (approximately 1 hour) and 
then at hourly intervals until the end of anaesthesia. 
The total time of halothane anaesthesia was calculated 
in terms of MAC-hours. An Engstrom Emma analyser was used 
in addition to the gas chromatography in the first three 
dogs studied in this group but it was found to be not as 
accurate as the gas chromatography. Anaesthesia was 
maintained for two hours before the administration of 
propranolol to allow stable haemodynamic conditions and 
continued throughout the four hour study period.
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5.3.3 Group 3 Isoflurane
Anaesthesia was maintained in this study with 
isoflurane 2.0 MAC (2.55%) in oxygen. End tidal 
isoflurane concentration was measured by gas 
chromatography as described above. Two hours of 
anaesthesia were administered before the propranolol was 
given and anaesthesia maintained until the end of the 
study. The total MAC-hours of anaesthesia was measured.
5.3.4 Group 4 Enflurane
In this group maintenance of anaesthesia with 
enflurane 2.0 MAC (4.2%) was attempted initially. 
However, it proved difficult to maintain cardiovascular 
stability at this concentration and extreme hypotension 
resulting in death occurred. It was decided to maintain 
anaesthesia with enflurane 1.5 MAC (3.15%) in oxygen in 
this group. End tidal concentration was measured by gas 
chromatography. Two hours of stable anaesthesia was 
administered before the propranolol was given and 
anaesthesia was maintained until the end of the study 
period.
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5.3.5 Group 5 Fentanyl - Atracurium-Nitrous oxide
In this group, following endotracheal intubation, the 
lungs were ventilated with nitrous oxide (66%) in 
oxygen. Muscle paralysis was achieved with atracurium 
using an initial dose of 0.3 mg/kg and subsequent bolus 
doses of 0.1 mg/kg every 20 min. Immediately after 
tracheal intubation an infusion of fentanyl was started. 
An initial short pilot study of infusions of fentanyl 
based on the regimens described by Murphy and Hug (312) 
was used to establish a suitable dosage. It was 
established that a two rate infusion, 0.75 pg/kg/min for 
20 min then 0.22 pg/kg/min for the remaining study 
period, produced a suitable anaesthetic state. That is, 
there was no response to an external stimulus of paw 
pressure in a dog which had received no muscle relaxant. 
This regimen was used for the study. Anaesthesia was 
maintained for one hour before propranolol 
administration and continued until the end of the four 
hour study period. At the end of anaesthesia the 
fentanyl infusion was stopped and no further atracurium 
given. The dog was then allowed to recover consciousness 
and resume spontaneous ventilation before extubation of 
the trachea. The total dose of fentanyl and of 
atracurium was recorded.
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5.3.6 Monitoring
In all the study groups ventilation was initially set 
to a tidal volume of 10 ml/kg. This was adjusted to 
maintain an arterial pC02 within the range of 4.6 - 5.5 
kPa on the basis of regular arterial blood gas 
measurements. Blood gas measurement was performed using 
a Corning automatic blood gas analyser which was 
calibrated each morning before the start of the study.
Arterial blood pressure was monitored continuously 
throughout anaesthesia by a pressure transducer and 
monitor attached to the femoral arterial cannula.
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5.4 Drug administration and blood sampling
5.4.1 Drug administration
The administration of the unlabelled and labelled 
propranolol was performed in an identical manner on each 
study day. On days 1 and 3 the dog was allowed to settle 
in the cage for 20 - 30 min before drug administration. 
On day 2, two hours of anaesthesia with a volatile agent 
or one hour of fentanyl anaesthesia was completed before 
the drugs were given.
The unlabelled propranolol was given into the portal 
vein over a lOmin period using a constant rate infusion 
pump. In all the studies 40mg of propranolol was used, 
with the exception of the enflurane study where 20mg 
were given. The smaller dose was used in the enflurane 
study to minimise the potentiation of the cardiovascular 
effects of the two drugs. At the start of the portal 
infusion, the labelled propranolol was given by bolus 
injection into the femoral vein. In all studies a dose 
of 200pCi of H3 -propranolol was used. The specific 
activity of this drug was 67 mCi/mg, only some 3ug of 
propranolol was given intravenously. Both cannulae 
(portal and femoral vein) were flushed with 20ml saline 
at the end of injection.
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5.4.2 Blood sampling
An identical protocol for blood sampling was followed 
on each day in all of the studies. All blood samples 
were taken from the femoral arterial cannula. The 
samples were taken over a four hour period. A blank 
control sample was taken each day before the propranolol 
administration as was a sample for measurement of plasma 
binding of propranolol. Following injection of the 
propranolol, 8ml of arterial blood was withdrawn every 
5min for the first hour and then every 15min over the 
next three hours. The blood was centrifuged for 10 min 
at 3000rpm and the plasma separated off and stored 
frozen at -20°C for subsequent measurement of plasma 
propranolol and H3-propranolol concentrations. Each 
blood sample was replaced by 20ml Hartman's solution to 
maintain blood volume. The analytical methods are 
described separately.
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5.5 Human study
5.5.1 Outline
This study compared the effect on hepatic blood flow 
and hepatic enzyme activity of cimetidine and enprostil. 
Nine volunteers were enrolled into a Latin Square design 
study involving three treatments, that is the 
administration of cimetidine, enprostil or placebo each 
for six days. The drugs were administered in a 
double-blind randomised fashion. There was a seven day 
washout period between each treatment. On the fifth day 
of each treatment hepatic blood flow was measured by the 
indocyanine green extraction method. On the sixth day 
hepatic blood flow and hepatic enzyme activity were 
measured by the dual route propranolol method.
5.5.2 Subjects
Nine male subjects of mean age 23.2 +/- 3.3 years 
(+/- SD) and mean weight of 73.8 +/- 9.3 kg were 
enrolled into this study. All subjects had an 
essentially negative past medical history, a normal 
physical examination and normal haematological and 
biochemical profile. No other drugs, alcohol or tobacco
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were taken throughout the study period. Written informed 
consent was obtained from all subjects.
5.5.3 Drugs
Each subject received, in a random order, six days 
treatment with each of the study drugs. A washout period 
of at least 8 days was observed between each treatment. 
The study drugs were enprostil 70)ig (two 35pg capsules) , 
cimetidine 600mg (two 300mg capsules) and placebo 
capsules. Enprostil is presented as a soft gelatin 
capsule and cimetidine in hard capsule form. Therefore, 
in order to maintain the blinding of the study, each 
dose consisted of two gelatin and two hard capsules. 
That is 2 enprostil / placebo soft capsules plus 2 
cimetidine / placebo hard capsules.
The dose schedules were ;
enprostil - 2 35pg enprostil soft capsules plus 2 
placebo hard capsules b.d. for six days,
cimetidine - 2 300mg cimetidine hard capsules plus 2 
placebo soft capsules b.d. for six days and
placebo - 2 placebo hard capsules plus 2 placebo soft 
capsules b.d. for six days.
The drugs were administered at 8am and 8pm on the six 
study days.
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5.5.4 Indocyanine green study
Hepatic blood flow was calculated for each subject 
using the indocyanine green method on the morning of the 
fifth day of each study period. Following an overnight 
fast, the subjects took their morning medication and 
reported to the study centre. After one hour lying 
supine to achieve basal conditions, they were given a 
dose of 0.5mg/kg indocyanine green by rapid (10 sec) 
bolus injection into an antecubital vein. Blood samples 
were taken from a vein in the contralateral arm at -1, 
1,2,3,4,5,6,7,8,10,12,15 and 20 minutes following 
injection. These samples were heparinised and 
centrifuged at 3000 rpm for 30 min.
The plasma ICG concentration was then measured 
immediately using a Beckman spectrophotometer with 
absorbance set at 810nm. On each occasion a calibration 
curve was constructed using the subjects own plasma (-1 
min sample). The clearance of ICG from the plasma was 
estimated from the slope (K) of the plot of the 
logarithm of the plasma ICG concentration against time, 
extrapolated to zero time concentration (CpO). This was 
then applied to the equation :
Clearance = K. Dose
CpO
The blood clearance, which was considered equivalent
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to the hepatic blood flow, was obtained by correcting 
the plasma clearance for the haematocrit, which was 
measured at the time of study.
5.5.5 Propranolol
Hepatic blood flow was calculated using the dual 
route propranolol method on the sixth day of each study 
period. The subject took the final (morning) dose of the 
drug, again after an overnight fast, and reported to the 
Clinical Research Center. After a 30min rest period 80mg 
of propranolol was taken orally and simultaneously 50)iCi 
H3- propranolol was injected intravenously. Blood 
samples were taken before the propranolol and at 5,15 
and 30min and 1,2,3,4,5,6,7 and 8 hours after the 
propranolol. The samples were centrifuged and the plasma 
separated off and stored for analysis of propranolol and 
H3- propranolol concentrations as described below. A 
sample was also taken before the propranolol 
administration for determination of the plasma binding 
of propranolol by equilibrium dialysis. The subjects 
were allowed to eat after the 4 hour sample had been 
taken. Blood pressure and heart rate were measured at 
hourly intervals during the study.
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5.5.6 Side effects
All subjects were questioned at the end of each phase 
as to any side effect they had noticed which may have 
been attributed to the study drug. An haematology 
screen, consisting of full blood count and differential 
white cell count, and a biochemical screen, consisting 
of urea, electrolytes and liver function tests (SMAC 
18), were taken before starting and at the end of each 
phase.
5.5.7 Summary
Day 1 - 6  Phase 1 - ICG study on day 5,
propranolol study on day 6 
Day 7 - 1 4  Washout period
Day 1 5 - 2 0  Phase 2 - ICG study on day 19,
propranolol study on day 20 
Day 21 - 28 Washout period
Day 29 - 34 Phase 3 - ICG study on day 33,
propranolol study on day 34
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5.6 Drug Analysis
5.6.1 Propranolol Assay
Propranolol concentrations were measured in plasma by 
a high pressure liquid chromatography (HPLC) method. 
Each plasma sample was prepared and analysed in
duplicate. A mean value of the two samples was used for
all calculations. The mobile phase for the HPLC was 
prepared daily and consisted of : 450ml acetonitrile, 
600ml distilled water, 10ml glacial acetic acid and 
0.15ml triethylamine. The mixture was de-aerated for 
40min using a sonicator. These reagents and all others 
used in this method were purchased from Burdick and
Jackson Inc and had been prepared by distillation in
glass. The internal standard was N-ethyl-propranolol. A 
standard propranolol solution containing 4>ig/ml 
propranolol hydrochloride was prepared for calibration 
of the system.
A standard calibration curve was run at the start and 
finish of each batch of samples. This was prepared as 
follows ;
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Propranolol conc._____ 0____ 25____ 50____ 100_____ 200
(ng/ml)
plasma 1
(ml)
standard propranolol 0
(Hi)
Internal standard 0
(Hi)
Distilled water 500
(Hi)
1 1 1 1
6.25 12.5 25 50
100 100 100 100
175 150 100 0
The samples for analysis were initially defrosted to 
room temperature. 1ml of the plasma was transfered to a 
17ml culture tube and lOOpl of internal standard and 1ml 
IN sodium hydroxide added and the tube vortexed. 8ml of 
1.5% isoamyl alcohol in heptane was then added and the 
mixture shaken for 5min then centrifuged at 1400rpm for 
lOmin. 7ml of the organic layer was then transfered to 
another tube and blown down with nitrogen to dryness in 
a 50°C water bath. The solute was then reconstituted by 
addition of 200ul methanol for injection into the HPLC 
system (313). A volume of 50pl was injected onto the 
HPLC for analysis.
This method showed excellent reproducability with a 
1-3% within day variability and serial analysis over the 
duration of all the analysis for the studies using the 
same plasma produced a varaibility of 3-7%. The pooled 
calibration samples for the human study demonstrated 
reproducability and linearity with a correlation
coefficient of 0.999, slope of 0.352 and intercept of
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-0.022.
5.6.2 HPLC system
The HPLC system was based on a Waters WISP 710A 
programmable autoinjector and pump which was linked to a 
Waters Data Module cosisting of an analyser and printer. 
The column was a Waters Bondapak C18 (250 x 4.6mm, lOp). 
The fluorometric detection used a Schoeffel FS970 
Fluoromonitor set at 228nm with a 295nm interference 
filter. The flow rate through the system was 2ml/min. 
The retention time for propranolol was around 6min and 
8min for the internal standard. The output of the 
detector was recorded on a dual channel recorder (Linear 
Instruments Corp.). The propranolol concentration was 
calculated, by the analyser, from the peak height ratio 
of the propranolol and internal standard. A linear 
regression was calculated between the height of the 
propranolol peak for the known concentrations in the 
calibration curves and the corresponding internal 
standard peaks. The unknown concentrations of 
propranolol were calculated by dividing the peak height 
of the propranolol trace by the slope of the linear 
regression.
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5.6.3 Scintillation counting
The 3H-propranolol concentrations were calculated by 
collecting the effluent of the HPLC throughout the 
period of each individual sample run during which the 
propranolol would appear in it. The retention time of 
the tritiated propranolol was similar to that of 
unlabelled propranolol. The collection of the effluent
was done manually from the 5th to 7th minute of each 
sample run, as the retention time of propranolol was 6 
minutes. The 4ml of effluent was then made up to 10ml 
with Unogel liquid scintillation counting fluid (Schwarz 
Chemicals). The radioactivity in each sample was then 
counted for lOmin in an Isocap 300 scintillation
spectrometer. This produced a measure of the
3H-propranolol concentration in dpm/ml (dpm = 
disintegrations per minute) (292).
5.6.4 Measurement of drug binding
The unbound fraction of propranolol in plasma was
measured by equilibrium dialysis. This technique
utilises. the equilibration across a semi-permeable
membrane of a protein-free phosphate buffer and a plasma 
sample which has a known amount of radio-labelled drug 
added to it. The free fraction is equal to the
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concentration in the buffer divided by the concentration 
in the plasma.
The buffer was prepared by adding 197ml 0.066M KH2P04 
and 803ml 0.066M Na2HP04.7H20. The pH of the solution
was adjusted to 7.4. The equilibration cells were 
prepared by placing the moistened semi-permeable 
membrane between the two ports. 1ml of buffer was placed 
in one port and 1ml of plasma which had been mixed with 
lOOul of 3H-propranolol was placed on the other. The 
sealed cells were allowed to equilibrate for 4hours in a 
water bath at 37aC. After equilibration lOOpl of each 
solution was added to separate scintillation vials with 
10ml of Unogel scintillation fluid (Schwarz). Each vial 
was scintillation counted for lOmin and the dpm 
calculated (314,315).
% free propranolol = dpm of buffer
dpm of plasma
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5.7 Calculations
5.7.1 Dose of drug injected
The dose of propranolol administered was calculated
by weighing the syringe before and after injection. The
propranolol was supplied at a concentration of lmg per
lml. The dose given (mg) was therefore equal to volume 
(ml) which in turn was equal to the difference in weight 
between the full and empty syringe.
The dose of H3-propranolol was calculated from the
concentration of and volume of drug injected. The 
concentration was calculated by storing a small aliquot 
of the fluid injected until the propranolol 
concentrations for that specific study were being run on 
the HPLC. A known quantity of this fluid (50jli1) was then 
added to each of the calibration samples for that run. 
This involves eight samples, four at the start of the 
run and four at the end. The eluent from these samples 
was collected and scintillation counted as described 
above. The mean count (dpm) of the eight samples of 
known volume was used to calculate the total amount of 
drug administered by measuring the volume injected as 
described above. This method of calculation accounts for 
any decay that may occur while stored between injection
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and measurement and, as the aliquot is put through the 
same extraction procedure as the samples, any 
contaminants, such as tritiated water, will be removed.
5.7.2 Area under the time-concentration curve
The area under the time concentration curve (AUC) was 
calculated for the propranolol and H3- propranolol for 
each subject on each day. This was calculated using the 
log-trapezoidal method on the Clinfo data handling 
package. This programme required an elimination constant 
to extrapolate the curve to infinity and therefore give 
an AUC to infinity. This was done with a curve fitting 
programme on the University DEC-10 mainframe computer. 
Each time-concentration curve was drawn out by hand on 
log graph paper. This allowed exclusion of any obvious 
outlying data points from the curve fit. The programme 
derived the elimination constant by linear regression 
analysis.
The calculation of these four basic values ? the 
intravenous dose of propranolol, the portal dose of 
propranolol and the areas under the time- concentration 
curves for the two routes of administration, allowed 
calculation of all the pharmacokinetic parameters. This 
included the systemic and portal clearance, the hepatic
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extraction ratio, bioavailability, the elimination
half-life, the volume of distribution and the hepatic 
plasma flow.
5.7.3 Clearance
Propranolol clearance following intravenous or 
systemic administration (Cls) was calculated as :
Cls = Xdiv
AUCiv (1)
where Xdiv is the dose of labelled propranolol
administered intravenously and AUCiv is the area under 
the time concentration curve calculated by the 
trapezoidal rule for the intravenous labelled 
propranolol.
The clearance of the unlabelled propranolol
administered into the portal vein (Clp) was calculated 
as :
Clp = Xdp
AUCp (2)
where Xdp is the dose of unlabelled drug administered 
into the portal vein and AUCp is the area under the time 
concentration curve for the unlabelled drug.
As propranolol is only metabolised in the liver and 
was injected into the portal vein, which is equivalent 
to 100% absorption following oral administration, the
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apparent clearance of the portally administered 
propranolol (Clp) is numerically equal to the total 
intrinsic clearance (Clint).
Thus Intrinsic clearance (Clint) = Clp = Xdp
AUCp
5.7.4 Hepatic extraction ratio
The hepatic extraction ratio (E) and bioavailability (F) 
were calculated from the formulae ;
F = Cliv 
Clp
and
F = (1-E)
5.7.5 Elimination constant and half life
The elimination rate constant (k ) was calculated by 
linear regression analysis as described above and
ii/ £. j. v aS •
Tl/2iv = 0.693
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5.7.6 Volume of distribution
The apparent volume of distribution (Vb) was 
calculated as :
Vb = Cls 
k
5.6.7 Hepatic plasma flow
The hepatic plasma flow (Q) was calculated as follows
By definition, following intraportal administration of a 
drug of dose (Xdp), the amount of the drug entering the 
systemic circulation is equal to XdpF where F is the 
fractional systemic availability.
Thus :
Cls = XdpF
AUCp (3)
But as Xdp/AUCp = Clp (equation 2) , and by definition 
F=l-E where E is the hepatic extraction ratio :
Cls = (l-E)Clp (4)
Also by Fick's principle : Cls = QE , where Q =
apparent hepatic plasma flow.
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Thus substituting for E in equation 4
Q = Cls.Clp 
Clp - CIS
Therefore by substituting for Clp and Cls (Equations 
1 and 2):
Hepatic plasma flow = Xdiv.Xdp
AUCivXdp - AUCpXdiv
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5.8 Statistical analysis
All data were stored on file on the Clinfo computer 
and in hard copy. The Clinfo system is an IBM based data 
handling system designed for medical and biological 
sciences. The package allows the construction of large 
spreadsheets for data storage and handling. It also 
provided basic mathematic functions and descriptive 
statistics as well as a wide range of parametric and 
non-parametric statistics.
In all the dog studies, for each group statistical 
comparisons between the 3 study days were performed 
using analysis of variance. Where this was significantly 
different (p<0.05) Student's t-test for paired data was 
carried out.
In all tests the level of significance was taken as 
p<0.05.
Comparison between the Groups was also by ANOVA and 
any significant differences were then subjected to a 
Mann-Whitney Test.
The demographic values for each study are presented 
as means and standard deviations. The calculated results 
for each study are presented in full, and as mean values 
with standard error of the mean.
In the human study comparison of the three drugs was
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by ANOVA. Where differences were found Student's t-test 
for pair data was used to compare the groups.
5.9 Ethical considerations
All the dog studies had received the approval of the 
Vanderbilt University Medical School Research Ethical 
Committee. The care and kenneling of the dogs was 
supervised by the Vanderbilt Animal Care Center, which 
complies with national animal care standards and is 
inspected annually for compliance with regulations.
The enprostil study had been approved by the Research 
Ethical Committee and was run, in conjunction with 
Syntex Research, in accordance with the regulations of 
the United States Food and Drug Administration for new 
drugs. All the participants in the study had received a 
full verbal and written explanation of the study and had 
given written consent (Appendix).
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Thesis Results
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6.4 Enflurane
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6.7 Enprostil and cimetidine study
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6.1 Control group
Three male mongrel dogs, of mean weight 22.3 +/- 
3.6kg, were studied on three consecutive days without
anaesthesia. The mean plasma concentrations for the
portally administered propranolol are shown against time 
in Figure 3 and that for the intravenous labelled
propranolol in Figure 4.
There were no significant differences in systemic 
clearance, hepatic plasma flow or plasma halflife on the 
three days. The intrinsic clearance, however, fell on 
Day 3 for two of the dogs. The individual values for the 
drug doses and derived data are shown for each day in 
Tables I-III , and the mean values (+/-SD) in Table IV.
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Symbols used in Tables
Dose of unlabelled propranolol given into 
portal vein
Area under time-concentration curve to 
infinity for portally administered drug
Dose of JH-labelled propranolol given 
intravenously
Area under time concentration curve to 
infinity for intravenously administered drug
Intrinsic clearance of propranolol
Systemic clearance of propranolol
Hepatic plasma flow calculated by 
dual-route method
Half life of intravenously administered 
propranolol
Apparent volume of distribution 
Hepatic extraction ratio 
Percentage of unbound propranolol
Table I
Control Study Day 1
DOG NO. 1 2 3
Dosep
(ng 107)
3.93 3.95 3.94
AUCp 1.93 
(ng.min.103)
1.55 1.82
Dose±v
(dpm.108)
1.89 2.04 2.00
Auciv
(dpm.min.
3.16
105)
3.11 3 .49
clint
(ml.min”1
2040
)
2550 2150
cls
(ml.min”1
600
)
660 570
H.P.F.
(ml.min”1
850
)
880 780
T1/2iv
(min)
54 38 119
vb
(litre)
47 36 98
E.R. 0.70 0.74 0.73
% free 6.8 4.8 10.6
Table II
Control Study Day 2
DOG NO. 1 2 3
Dosep
(ng 107)
3.92 3.93 3.94
AUCp 2.62
(ng.min.103)
1.86 1.69
Dose±v
(dpm.108)
1.86 2.20 2.05
Auciv
(dpm.min.
3.04
105)
2.60 3.70
clint 
(ml.min”1
1490
)
2110 2320
cls
(ml.min”1
610
)
850 550
H.P.F.
(ml.min”1
1030
)
1410 730
Tl/2±v
(min)
58 42 72
vb
(litre)
51 53 57
E.R. 0.60 0.64 0.74
% free 7.8 5.0 7.2
Table III
Control Study Day 3
DOG NO. 1 2 3
Dosep
(ng 107)
3.94 3.91 3.96
AUCp 2.86
(ng.min.103)
2.42 2.91
Doseiv
(dpm.108)
2.07 2.07 2.07
Auciv
(dpm.min.
3.15
105)
3.78 3.05
clint 
(ml.min”1
1380
)
1610 1360
cls
(ml.min"1
650
)
550 580
H.P.F.
— 1(ml.mm x
1250
)
830 1340
T1/2iv
(min)
55 47 94
vb
(litre)
52 38 92
E.R. 0.53 0.66 0.58
% free 7.6 5.2 5.5
Table IV
Control study 
Mean values (SD)
DAY 1 2 3
clint 
(ml. min”
2250 
, (27.0) 
ml)
1980
(420)
1450
(140)
cls
(ml. min”
610 
n (40)
670
(150)
590
(55)
H.P.F.
(ml.min”
840
(50)
V
1060
(340)
1140
(270)
T V 2 iv
(min)
70
(24)
57
(18)
65
(13)
vb
(litre)
60
(30)
54
(3)
61
(25)
E.R. 0.73
(.02)
0.65
(.08)
0.60
(.07)
% free 7.4 6.7 
(2.9) (1.4)
6.1
(1.3)
6.2 Halothane Anaesthesia
Six male mongrel dogs of mean weight 22.9 +/- 4.5 kg 
were studied.
The mean plasma concentrations of the portally 
administered propranolol at each time point on the three 
study days are shown in Figure 5. This shows an increase 
in the propranolol concentration and a slowing of the 
rate of elimination during anaesthesia when compared to 
the pre-anaesthetic values. These changes are still 
evident at 24 hours after anaesthesia.
The mean plasma concentrations of the H3- labelled 
propranolol on the three study days are plotted against 
time in Figure 6. This also demonstrates an increase in 
plasma propranolol concentration and decreased 
elimination rate during halothane anaesthesia which has 
not returned to pre-anaesthesia values 24 hours later.
The individual values for each study day are shown in 
Tables V-VII and the mean values for each day in Table 
VIII. The changes in the mean values for intrinsic 
clearance, systemic clearance and hepatic plasma flow 
are shown in Figure 7.
The intrinsic clearance of propranolol, that is the 
clearance of the portally administered drug, had a mean
153
value of 2110 +/- 298 ml.min1 on Day 1. This decreased 
by 62% to 799 +/- 233 ml.min' during halothane
anaesthesia and was still decreased by almost 50% to 
1095 +/- 331 ml.min' on Day 3.
The systemic clearance of propranolol, the clearance of 
the labelled intravenous drug, had a mean value of 470 
+/- 33 ml.mm on Day 1. This decreased by 40% to 280
+/- 38 ml.min' during anaesthesia and had recovered to
333 +/- 57 ml.min'on Day 3.
The mean elimination half-life of the intravenously 
administered propranolol was increased from 87 +/- 12
min on Day 1 to 155 +/- 23 min during anaesthesia and
returned to 94 +/- 12 min on Day 3.
The hepatic extraction (E) of propranolol was 
decreased from a mean value of 0.75 +/- 0.04 on day 1 to 
0.59 +/- 0.05 on Day 2 and 0.60 +/- 0.07 on Day 3. This
resulted in an increased bioavailability (1 - E) of
propranolol.
The volume of distribution did not change 
significantly throughout the study period.
The plasma binding of propranolol was reduced 
significantly during anaesthesia resulting in an 
increase in the free fraction from a mean of 7.1 +/-
1.0% on Day 1 to 9.6 +/- 1.4% on Day 2 and returning to
8.1 +/- 0.9% on Day 3.
The calculated hepatic plasma flow demonstrated a 
non-significant decrease from a mean value of 642 +/- 80
154
. . •*ml.mm on Day 1 to 473 +/- 47 ml.mm on Day 2 and
returning to 583 +/- 83 ml.min on Day 3.
The mean duration of halothane anaesthesia was 11.7 
+/- 0.4 MAC hours.
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TABLE V
Halothane Study day 1
DOG NO. 1 2 3 4 5 6
Dosep
(ng 107)
3 . 80 4.06 4.03 3.97 4. 00 3 .98
AUCp 1.78 
(ng.min.104)
2.23 2.75 2.61 1.75 1.16
Doseiv 
(dpm.108)
1.28 1.28 1.67 1.73 1.42 1.77
AUCiv 
(dpm.min.
2.40
105)
3.59 3.52 2.88 3.13 4.09
clint 
(ml.min”1
2130
)
1820 1460 1520 2290 3440
cls
(ml.min”1
510
)
360 470 600 450 430
H.P.F.
(ml.min”1
660
)
440 690 990 570 490
Tl/2±v
(min)
58 128 70 61 97 110
vb
(litre)
44 66 47 53 63 68
E.R. 0.76 0.80 0.68 0.61 0.80 0.87
% free 5.9 7.1 5.1 4.5 9.4 10.8
TABLE VI
DOG NO. 1
Halothane Study 
2 3
Day 2 
4 5 6
Dosep 4.05 3.98 . 3.99 4.08 3.97 3.96
(ng 107)
AUCp 2.09 
(ng.min.104)
7.83 1.37 4.73 5.92 7.41
Doseiv 
(dpm.108)
1.10 1.36 1.52 1.72 1.71 1. 67
AUCiv 
(dpm.min.
2.21
105)
4.87 1.02 5.72 5.74 7.54
clint 
(ml.min”1
1900
)
510 290 860 700 530
cls
(ml.min”1
430
)
280 150 300 300 220
H.P.F.
(ml.min”1
560
)
620 310 460 580 380
Tl/2iv 73 209 182 83 135 218
(min)
vb 73 84 39 36 58 70
(litre)
E.R. 0.77 0.45 0.49 0.65 0.58 0.59
% free 8.8 7.8 6.3 7.9 11.7 15.7
TABLE VII 
DOG NO. 1
Halothane Study 
2 3
Day 3 
4 5 6
Dosep 4.19 4.02 3.87 3.97 3.91 3.99
(ng 107)
AUCp 1.76 
(ng.min.104)
6. 60 5.54 7.38 2.06 8.27
Doseiv 1.33 1.43 1.81 1.42 1.03 2.05
(dpm.108)
AUCiv 2.19 
(dpm.min.105)
5.55 5.36 4.90 4.61 7.12
clint 
(ml.min”1)
2340 610 700 540 1900 480
cls 610 260 340 290 220 290
(ml.min”1)
H.P.P. 820 440 650 610 250 720
• — i(ml. m m  )
T1/2 iv
(min)
73 146 70 77 91 107
(litre)
64 54 33 32 29 44
E.R. 0.74 0.58 0.52 0.47 0.88 0.40
% free 8.0 7.9 6.0 5.6 10.8 10.6
Table VIII
Halothane study 
Mean values (SEM)
DAY 1 2 3
clint 
(ml.min"
2110
(300)
'h
4?
800
(230)
1100
(330)
cls 470 280* 330
- (30) (40) (60)
(ml .min”
H.P.F. 640 470 580
, (80) (50) (80)
(ml.min”X)
Tl/2±v 87 155* 94
(12) (23) (12)
(min)
57 60 43
(4) (8) (6)
(litre)
E.R. 0.75 0.59* 0.60*
(.04) (.05) (.07)
% free 7.1 _9.6 8.1
(1) (1.4) (.9)
* p<0.05 compared with Day 1
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6.3 Isoflurane anaesthesia
Six male mongrel dogs of mean weight 19.2 +/- 3.7 kg 
were studied. The duration of isoflurane anaesthesia was
11.2 +/-0.8 MAC hours.
The mean plasma concentrations of the intraportally 
administered propranolol are shown plotted against time 
in Figure 8. This demonstrates an increase in plasma 
concentration of propranolol during anaesthesia which 
has returned to the pre-anaesthesia level 24 hours 
later.
The mean plasma concentrations of the intravenously 
administered H3- labelled propranolol are shown in 
Figure 9. This shows a similar pattern of change to that 
of the intraportal route.
The individual values for each study day are shown in 
Tables IX-XI , and the mean values for each day in Table 
XII. The changes in the mean values for intrinsic 
clearance, systemic clearance and hepatic plasma flow 
are shown in Figure 10.
The intrinsic clearance of propranolol fell by over 
50% during anaesthesia from a mean pre-anaesthetic value
-\ -i
of 1552 +/- 210 ml.min to 723 +/- 50 ml.min (p<0.05).
-i
On Day 3, this had returned to 1853 +/- 556 ml.min
156
(NS) .
The systemic clearance of propranolol decreased 
significantly from a mean value on Day 1 of 479 +/- 56
• “ i , *i , ,
ml. m m  to 286 +/- 41 ml. m m  during anaesthesia
(p<0.05). This fall of 40% during anaesthesia was not 
evident 24 hours later when the mean value was 454 +/-
-i
51 ml.min.
The mean elimination half-life of the intravenously 
administered propranolol was significantly increased 
from the Day 1 value of 68.5 +/- 6.7 min to 171.6 +/-
42.5 min during anaesthesia (p<0.05). This had fallen to
84.6 +/- 8.9 min on Day 3.
The hepatic extraction of propranolol fell from 0.66 
on Day 1 to 0.61 on Day 2. These changes are reflected 
in the bioavailability.
There was no significant change in the volume of 
distribution throughout the study. There was no 
significant change in the free fraction of propranolol 
during the study.
There was a non-significant decrease in the 
calculated hepatic plasma flow from a mean value on day
-» . - i
1 of 884 +/- 304 ml.mm to 506 +/- 96 ml.mm during
. -I
anaesthesia and a return to 721 +/- 79 ml.mm on Day 3.
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Table IX
Isoflurane Study Day 1
DOG NO. 1 2 3 4 5 6
Dosep 
(ng 107)
4.02 3.94 3.92 4.04 * 3.88 4.00
AUCp 1.86
(ng.min.104)
3.70 3.28 1.87 2.38 3 . 66
Dose^v 
(dpm.108)
1.94 1.86 1.48 1.40 1.67 1.32
Auciv
(dpm.min.
3.84
105)
2.50 4.21 3.06 3.42 4.43
clint 
(ml.min”1
2160
)
1060 1200 2160 1630 1090
cls
(ml.min”1
500
)
740 350 460 490 330
H.P.F.
(ml.min"1
660
)
2500 500 580 700 470
T1/2iv
(min)
90 80 53 47 72 70
vb
(litre)
66 85 27 31 51 33
E.R. 0.77 0.69 0.70 0.79 0.70 0.70
% free 13.0 13.2 8.5 5.7 9.3 11.0
Table X
Isoflurane Study Day 2
DOG NO. 1 2 3 4 5 6
Dosep
(ng 107)
4.00 3.93 4.00 4.03 4.21 3.97
AUCp 7.33 
(ng.min.104)
4.99 6.68 5.21 4.88 5.17
Doseiv
(dpm.108)
1.36 1.87 1.93 1.54 1.40 1.48
AUCiv
(dpm.min.
10.9
105)
4.97 7.07 4.04 6.31 4.17
clint 
(ml.mm
550
)
790 600 770 860 770
C1S
(ml.min-1
130
)
380 270 380 220 330
H.P.F.
• — i(ml. m m
160
)
720 500 750 300 590
Tl/2iv
(min)
370 163 111 80 170 132
vb
(litre)
67 89 44 44 55 64
E.R. 0.77 0.52 0.54 0.50 0.74 0.56
% free 13.9 11.8 9.5 9.0 14.1 12.7
Table XI
Isoflurane Study Day 3
DOG NO. 1 2 3 4 5 6
Dosep
(ng 107)
3.92 3.91 3.99 4.21 4.26
AUCp 8.62
(ng.min.104)
2.05 3.15 1.10 2.35
Doseiv
(dpm.108)
1.77 1.94 1.90 1.72 1.58
AUCiv
(dpm.min.
5.99
105)
3.23 3.82 3.60 3.99
clint 
(ml.min”1
450
)
1910 1270 3820 1810
cls
(ml.min”1
290
)
600 500 480 400
H.P.F.
(ml.min”1
850
)
880 820 540 520
T1/2iv
(min)
100 97 57 70 100
vb
(litre)
43 84 41 49 57
E.R. 0.65 0.68 0.60 0.87 0.78
% free 13.1 13.6 8.0 7.9 11.6
Table XII
Isoflurane 
Mean values
DAY 1
study
(SEM)
2 3
clint 1550 720* 1850
(210) (50) (550)
(ml .min”-1-)
cls 480 290* 450
(50) (40) (50)
(ml.min ■*■)
H.P.F. 880 510 720
(300) (100) (80)
(ml.min ■*■)
T!/2iv 69 172* 85
(7) (43) (9)
(min)
vb 49 60 55
(10) (7) (8)
(litre)
E.R. 0.66 0.61 0.66
(.07) (.05) (.09)
% free 11.1 11.9 12.1
(.7) (.8) (1.5)
* p<0.05 compared with Day 1
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6.4 Enflurane anaesthesia
After initial studies with three dogs, which are not
included in the results, it was found to be unsuitable
to administer 2MAC of enflurane as this produced 
profound cardiac depression in the dogs. This was of a
much greater magnitude than was found with the other 
agents. It was therefore decided to used 1.5 MAC in the 
enflurane study as this gave a comparable change in the 
cardiovascular parameters. The dose of propranolol was 
also reduced to 20mg given intraportally. This was still 
cardiodepressant and it was felt appropriate to continue 
the study for a third day in only two of the dogs.
Five male mongrel dogs of mean weight 20.8 +/-3.0 kg 
were studied.
The mean plasma concentration of the portally 
administered propranolol on the two study days is shown 
against time in Figure 11. This demonstrates an increase 
in plasma concentration and slowing of elimination of 
propranolol during enflurane anaesthesia. The individual 
concentration - time curves for the two dogs studied for 
a third day are not shown.
The mean plasma concentrations of the H3- labelled 
propranolol are shown against time in Figure 12. There
158
is again a slowing of elimination and increased
concentration of propranolol.
The individual values for the five dogs studied for 2 
days are shown in Tables XIII and XIV, and the values 
for the two dogs studied for a third day are in Table
XV. The mean values for days 1 and 2 are shown in Table
XVI. The changes in the mean values for intrinsic
clearance, systemic clearance and hepatic plasma flow 
are shown in Figure 13.
The intrinsic clearance of the intraportally
administered propranolol fell significantly from 3749
-c -i
+/- 880 ml.min on Day 1 to 1197 +/- 206 ml.min during
anaesthesia (p<0.05).
The systemic clearance of the intravenously
administered propranolol also fell significantly from
. -» , - i
672 +/- 85 ml.mm on Day 1 to 314 +/- 40 ml.mm on Day
2 (p<0.05).
The intravenous elimination half-life was
significantly increased from 59 +/- 6 min on Day 1 to
167 +/- 28 min during anaesthesia (p<0.05).
There was no change in the apparent volume of
distribution but the hepatic extraction fell from 0.80 
+/- 0.02 to 0.72 +/- 0.02 during anaesthesia (p<0.05).
The calculated hepatic plasma flow fell significantly 
by approximately 50%
-I -f
from 835 +/- 97 ml.min on Day 1 to 436 +/- 62 ml.min
on Day 2 (p<0.05).
159
A mean dose of 9.25 +/“ 0.58 MAC hours of enflurane was 
administered during anaesthesia.
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Table XIII
Enflurane Study Day 1
DOG NO. 1 2 3 4 5
Dosep
(ng 107)
3.97 1.92 2.05 1.94 2.05
AUCp 1.63 
(ng.min.103)
2.84 1.02 4.07 7.31
Dose±v
(dpm.108)
1.43 1.86 1.98 1.74 2.10
Auciv
(dpm.min.
2.63
105)
2.22 4.77 2.04 2.95
clint 
(ml.min”1
2440
)
6720 2010 4750 2800
cls
(ml.min”1
540
)
840 420 850 710
H.P.F.
(ml.min”1
700
)
960 520 1040 950
T1/2iv
(min)
53 49 83 61 49
vb
(litre)
41 59 50 76 50
E.R. 0.77 0.87 0.79 0.82 0.74
% free 8.2 5.7 6.1 7.6 6.0
Table XIV
Enflurane Study Day 2
DOG NO. 1 2 3 4 5
Dosep 
(ng 107)
3.98 1.98 1.94 1.94 1.91
AUCp 3.50 
(ng.min.104)
1.27 3.35 1.12 1.95
Doseiv
(dpm.108)
2.83 2.11 1.82 2.18 2.14
AUCiv 6.94 
(dpm.min.105)
5.59 9.95 6.54 7.97
clint 
(ml.min”1)
1140 1560 580 1730 980
cls
(ml.min”1)
410 380 180 330 270
H.P.F.
(ml.min”1)
630 500 270 410 370
Tl/2iv
(min)
141 101 270 159 162
vb
(litre)
83 55 71 76 63
E.R. 0.64 0.75 0.68 0.80 0.72
% free 10.8 11.0 10.0 10.5 8.2
Table XV
Enflurane Study Day3 
DOG NO. 1 2  3 4 5
Dosep
(ng 107)
• 2.02 1.93
AUCp 1.53 5.21
(ng.min.104)
Doseiv 2.17 2.07
(dpm.108)
AUCiv 3.20 9.20
(dpm.min.105)
clint 1320 370
(ml.min”1)
cls 680 220
(ml.min”1)
H.P.F. 1400 570
(ml.min”1)
T1/2iv 63 90
(min)
vb 61 29
(litre)
E.R. 0.48 0.39
% free 7.3 5.8
Table XVI Enflurane study 
Mean values (SEM)
DAY 1 2  3
Clint 3750 
(880)
(ml.min x)
1200*
(200)
Cl- 670 310*
, (90) 
(ml.min -1-)
(40)
H.P.P. 840 440*
(100) (60)
(ml.min ■*■)
Tl/2iv 59 167*
(6)
(min)
(28)
Vb 55 70
(6)
(litre)
(5)
E.R* 0.80 0.72*
(.02) (.02)
% free 6.7 10.1*
(.5) (.5)
* p<0.05 compared with Day 1
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6.5 Fentanyl - Atracurium - Nitrous Oxide
Anaesthesia
Six male mongrel dogs of mean weight 21.3 +/-7.1 kg 
were studied.
The mean plasma concentration of the portally
administered propranolol for each of the three study
days is shown against time in Figure 14. This shows an
increase in plasma concentration and slowing of
propranolol elimination during anaesthesia which is
almost fully reversed 24 hours later.
The mean plasma concentrations of the intravenously
administered H-3 labelled propranolol are shown against
time in Figure 15. This again shows an increase in
concentration during anaesthesia which has returned to
the pre-anaesthetic level by 24 hours.
The individual values for each study day are shown in
Tables XVII-XIX , and the mean values for each day in
Table XX. The changes in the mean values for intrinsic
clearance, systemic clearance and hepatic plasma flow
are shown in Figure 16.
The intrinsic clearance of the propranolol fell from
a mean value of 1775 +/- 385 ml.min on Day 1 to 664 +/- 
-i .95 ml.mm during anaesthesia, a fall of 63% (p<0.05).
-i
On Day 3 the mean value of 1649 +/- 445 ml.min was not
161
significantly different from that on Day 1.
The systemic clearance of propranolol fell by 35%
from a mean value of 536 +/- 29 ml.min' on Day 1 to 347 
. -l
+/- 41 ml.mm during anaesthesia (p<0.05). There was no
significant difference between the Day 3 value of 615 
+/- 84 ml.min' and that of Day 1.
The mean elimination half-life of the intravenously
administered propranolol increased from 65 +/- 6 min on
Day 1 to 98 +/- 9 min on Day 2 (p<0.05). On day 3 the
value was 65 +/- 4 min (NS).
The hepatic extraction of propranolol fell from 0.61 
+/-0.04 on Day 1 to 0.46 +/-0.03 during anaesthesia and 
returning to 0.53 +/-0.08 on Day 3.
The volume of distribution did not change
significantly throughout the study.
The free fraction of propranolol increased from a 
mean of 7.0 +/- 0.8% on Day 1 to 8.4 +/- 0.6% on Day 2 
(p<0.05) and was 7.8 +/- 0.7% on Day 3 (NS).
The calculated hepatic plasma flow showed a
-i
non-significant decrease of 27% from 1044 +/- 233 ml.min
-i
on Day 1 to 762 +/- 99 ml.min during anaesthesia. The
-i
value for Day 3 was 1253 +/- 194 ml.min (NS).
The mean dose of fentanyl administered was 1.565
+/-0.15 mg and of atracurium 73.0 +/-6.5 mg. The mean
duration of anaesthesia was 5.38 +/-0.08 hours.
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Table XVII
DOG NO. 1
Fentanyl
2
Study Day 1 
3 4 5 6
Dosep
(ng 107)
4.06 3.89 4.01 3.96 3.91 4. 01
AUCp 1.41 
(ng.min.104)
1.94 6.49 3.15 3.63 1.42
Doseiv
(dpm.108)
2.42 1.12 1.89 1.67 1.67 1.66
AUCiv
(dpm.min.
3.74
105)
2.04 3.93 2.84 3 .55 3.47
clint 
(ml.min”1
2870
)
2010 620 1260 1080 2820
cls
(ml.min”1
650
)
550 480 580 480 480
H.P.F.
(ml.min”1
840
)
760 2160 1100 840 580
Tl/2±v
(min)
81 66 79 40 68 52
vb
(litre)
76 53 55 34 46 36
E.R. 0.78 0.73 0.30 0.54 0.56 0.83
% free 10.3 7.6 5.8 5.1 5.4 5.4
Table XVIII
Fentanyl Study Day 2
DOG NO. 1 2 3 4 5 6
Dosep
(ng 107)
3.98 3.93 3.90 3.92 3.97 3.92
AUCp 5.36 
(ng.min.104)
6.49 6.35 9.15 7.86 3.62
Doseiv 
(dpm.108)
1.56 1.56 2.54 1.67 1.72 1.51
Auciv
(dpm.min.
4.64
105)
3.99 8.91 6.60 5.94 2.86
clint 
(ml. m m
740
)
610 610 430 510 1080
c^s
• —  i(ml. m m
340
)
390 280 250 290 530
H.P.F.
—  1(ml. m m
610
)
1110 530 620 680 1020
Tl/2iv
(min)
122 85 96 80 129 75
vb
(litre)
59 48 39 29 54 57
E.R. 0.55 0.35 0.53 0.41 0.43 0.51
% free 8.6 9.8 7.9 7.5 7.2
Table XIX
Fentanyl Study Day 3
DOG NO. 1 2 3 4 5 6
Dosep
(ng 107)
3.92 3.89 3.93 3.94 4.01 3.93
AUCp 4.62 
(ng.min.104)
6.48 1.43 3.21 3.33 1.21
Doseiv 
(dpm.108)
2.06 1.81 2.06 1.68 1.66 1.95
AUCiv 4.08 
(dpm.min.105)
3.90 3.08 3.09 3.32 1.93
clint 
(ml.min"'1)
850 600 2760 1230 1200 3260
cls
(ml.min"1)
510 470 670 540 500 1010
H.P.F.
(ml.min"1)
1250 2090 880 980 850 1460
T1/2iv
(min)
71 75 69 50 68 55
vb
(litre)
51 51 66 39 49 80
E.R. 0.40 0.22 0.75 0.55 0.58 0.69
% free 6.0 7.7 7.5 7.2 8.4 6.3
Table XX Fentanyl study 
Mean values (SEM)
DAY 1 2 3
Clint 1780 
, (380) 
(ml.min ■L)
4*
660
(100)
1650
(440)
Cl,, 540 350* 620
. (30) (40) (80)
(ml.min -1-)
H.P.F. 1040 760 1250
(230) 100) 190)
(ml.min •**)
Tl/2iv 65 _ _ * 98 65
(12) (23) (12)
(min)
Vb 50 48 56
(6) (5) (6)
(litre)
E.R. 0.61 0.46* 0.53
(.04) (.03) (.08)
% free 7.0 8.4* 7.8
(.8) (.6) (.7)
* p<0.05 compared with Day 1
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6.6 Comparison between the groups
The broad effect of all four anaesthetic regimens was 
similar. The effect of anaesthesia in the four groups on 
the disposition of propranolol as measured by the 
intrinsic clearance, systemic clearance, hepatic blood 
flow and elimination half-life, is shown in Table XI, 
where the results are expressed as percentages of the 
control value, ie. the Day 1 value in each group.
The values obtained for intrinsic clearance in all 
five studies are compared in Figure 17 and the change in 
intrinsic clearance from Day 1 to Days 2 and 3 in Figure 
18. The values for systemic clearance are compared in 
Figure 19 and the change from Day 1 in Figure 20. The 
hepatic blood flow is shown in Figure 21 and the change 
from Day 1 in Figure 22. The calculated elimination 
half-life is shown in Figure 23 for all five groups.
Statistical comparison of the initial values (Day 1) 
for all five groups demonstrated no significant 
difference between the groups for systemic clearance, 
hepatic blood flow and intravenous half-life. ANOVA 
demonstrated a difference in intrinsic clearance between 
the groups. Subsequent inter-group analysis showed a 
significant difference for the values for intrinsic 
clearance between the enflurane and isoflurane groups 
(p<0.05).
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The values for intrinsic and systemic clearance and 
intravenous half-life on Day 2 were not significantly 
different for all four anaesthetic agents, but all were 
significantly different from the control group. Hepatic 
blood flow in the fentanyl group was significantly 
different from the others (p<0.05). The extent of change 
from control to during anaesthesia ie Day 1 - Day 2 
value, was not significantly different for all four 
anaesthetic regimens with respect to intrinsic and 
systemic clearance, intravenous half-life and hepatic 
blood flow.
A comparison of the values obtained in the halothane, 
isoflurane and fentanyl groups on Day 3 demonstrated no 
significant difference between the groups for intrinsic 
or systemic clearance. However the hepatic blood flow in 
the fentanyl group was significantly greater (p<0.05).
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TABLE XXI
Comparison of effect of anaesthesia 
Expressed as percentage of mean Day 1 value
clint cls HPF T1/2iv
DAY 2
Halothane 38 60 73 178
Isoflurane 47 60 58 249
Enflurane 32 47 52 283
Fentanyl 37 65 73 150
Control 88 109 126 81
DAY 3
Halothane 52 70 90 107
Isoflurane 118 94 82 123
Enflurane
Fentanyl 92 113 120 100
Control 66 97 135 91
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HEPATIC PLASMA FLOW
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Figure 22
Change in Hepatic Plasma Flow
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6.7 Enprostil and Cimetidine Study
All nine subjects completed the three phases of the 
study.
The mean time concentration curve for the orally 
administered propranolol during the three phases, 
placebo, cimetidine and enprostil, is shown in Figure
24. The plasma concentration of propranolol was 
increased during the cimetidine phase. The oral 
clearance of propranolol was significantly decreased 
during the cimetidine phase to 2072 +/- 261 ml.min1 when 
compared to the placebo phase value of 4152 +/- 871 
ml.mm (p<0.05). The value during the enprostil phase, 
4272 +/- 652 ml.min was not significantly different
from the placebo value.
The time-concentration curve for the intravenous 
propranolol on the three study days is shown in Figure
25. The clearance of the intravenously administered H3- 
labelled propranolol was also significantly reduced
-i
duing the cimetidine phase to 727 +/- 64 ml.min from
-I
the placebo value of 897 +/- 83 ml.min (p<0.05). The
-t
enprostil value of 917 +/- 58 ml.min was not
significantly different from the placebo value. The 
intravenous half-life of the labelled propranolol was 
225 +/- 11 min during the placebo phase. This was
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significantly increased during the cimetidine phase to 
270 +/- 12 min but not significantly different during
the enprostil phase at 213 +/- 10 min.
The individual values for the three study phases are 
shown in Tables XXII-XXIV. The mean values for the three 
study phases are given in Table XXV. The mean values for 
intrinsic clearance, systemic clearance and hepatic 
plasma flow are shown in Figure 26.
The decrease in oral clearance during the cimetidine 
phase is reflected in the increase in bioavailability 
which increased from 26 +/- 3 % with placebo to 37 +/-3 
% during the cimetidine phase (p<0.05). The enprostil 
treatment did not alter the bioavailability 
significantly (25 +/- 3%).
The plasma protein binding of propranolol was not 
significantly altered by any of the phases. The free 
fraction was 13.0 +/“ 1*1% during placebo, 13.3 +/- 0.8% 
during cimetidine and 12.7 +/- 0.9% during enprostil
phase.
The calculated hepatic plasma flow using the propranolol 
method was not significantly different during the three 
phases being 1211 +/- 98, 1167 +/- 93 and 1247 +/- 88
ml.min* during the placebo, cimetidine and enprostil 
phases respectively. The hepatic plasma flow calculated 
from the indocyanine green clearance produced lower 
values but these were not significantly different 
between the three phases (Table XXVI). The values were
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Table XXIIa Placebo Study Day
Subject 1 2 3 4 5
DoseQ 
(ng 107)
8.0 8.0 8.0 8.0 8.0
AUCq 2.35 
(ng.min.104)
4.78 1.04 1.68 0.90
Doseiv
(dpm.108)
1.86 1.64 2.00 1.67 1.83
Auciv
(dpm.min.
1.70
105)
2.82 1.54 1.80 1.72
clint
(ml.min
3410
)
1680 7720 4760 8850
cls
(ml.min"1
1100
)
580 1290 930 1070
H.P.F.
(ml.min”1
1620
)
900 1550 1150 1210
Tl/2iv
(min)
279 273 212 197 184
E.R. 0. 68 0.65 0.83 0.81 0.88
% free 17.6 8.6 16.7 11.0 16.8
Table XXIIb Placebo Study Day
Subject 6 7 8 9
Dose0 
(ng 107)
8.0 8.0 8.0 8.0
AUCq 4.08 
(ng.min.104)
4.16 3.22 1.74
Doseiv 
(dpm.108)
1.51 1.33 1.78 1.80
AUCiv
(dpm.min.
2.58
105)
2.11 1.90 1.90
clint 
(ml.min”1
1960
)
1930 2480 4600
cls
—1(ml.min
590
)
630 940 950
H.P.F.
(ml.min”1
830
)
930 1510 1190
T1/2iv
(min)
226 232 213 209
E.R. 0.70 0.67 0.62 0.79
% free 9.1 12.1 13.2 12.4
Table XXIIIa Cimetidine Study Day
Subject 1 2 3 4 5
DoseQ 
(ng 107)
o•CO o•CO o•00 00 • o
o•00
AUC0 2.35 
(ng.min.104)
6.72 2.87 2.91 3.97
Dose±v
(dpm.108)
1.88 1.52 1.85 1.93 1.41
Auciv
(dpm.min.
ot"' 
^
• 
in  
H 
o
 
H
3.29 1.95 2.41 2.37
clint
(ml.min
3000
)
1190 2790 2750 2020
C1S
(ml.min-1
1040
)
460 950 800 600
H.P.F.
(ml.min-1
1600
)
760 1440 1130 850
T1/2iv
(min)
275 314 248 308 211
E.R. 0.65 0.61 0.70 0.71 0.70
% free 15.6 9.7 16.6 14.9 11.7
Table XXIIIb Cimetidine Study Day
Subject 6 7 8 9
Dose0 8.0 8.0 8.0 8.0
(ng 107)
AUCq 6.08 6.99 5.06 2.79
(ng.min.104)
Doseiv 1.51 1.62 1.21 1.39
(dpm.108)
AUCiv 2.70 2.56 1.80 1.69
(dpm.min. 105)
clint • 1320 1150 1580 2870
(ml.min”1)
cls 570 630 670 820
(ml.min”1)
H.P.F. 990 1410 1170 1160
(ml.min”1)
Tl/2±v 291 275 291 217
(min)
E.R. 0.57 0.45 0.58 0.71
% free 10.5 12.4 13.4 15.3
Table xxiVa Enprostil Study Day
Subject 1 2  3 4 5
DoseQ 
(ng 107)
00 • o o•
CO o•CO o•CO o•CO
AUC0 1.08 
(ng.min.104)
4.29 1.04 1.48 2.34
Doseiv
(dpm.108)
1.81 1. 65 2.00 1.56 1.64
AUCiv
(dpm.min.
1.52
105)
2.82 1.54 2.00 2.13
clint 
(ml.min"1
7390
)
1870 5310 5390 3420
cls
(ml .min"1
1190
)
750 1210 780 820
H.P.F.
(ml.min"1
1420
)
1250 1570 910 1070
T1/2iv
(min)
179 206 195 184 248
E.R. 0.84 0.60 0.77 0.86 0.76
% free 14.5 13.5 17.1 11.0 8.3
Table XXIVb Enprostil Study Day
Subject 6 7 8 9
DoseQ 
(ng 107)
o
•
CO o•CO o•CO 8.0
AUCq 2.99 
(ng.min.104)
3.56 2.19 1.23
Doseiv 
(dpm.108)
1.81 1.93 1.82 1.42
Auciv
(dpm.min.
2.25
105)
2.03 1.94 1.76
clint 
(ml.min”1
2670
)
2250 3650 6500
cls
(ml.min”1
810
)
950 940 810
H.P.F.
(ml.min”1
1160
)
1650 1270 920
Tl/2±v
(min)
267 228 210 196
E.R. 0.70 0.58 0.74 0.88
% free 12.9 10.3 12.6 14.2
Table XXV
Enprostil study 
Mean values (SD)
Drug PI a Cim Enp
Clint 4150 
(870)
(ml.min ■*•)
2070*
(260)
4270
(650)
Cl*. 900 
n (80) 
(ml.min -*•)
730*
(60)
920
(60)
H.P.F. 1210 
Pr°P , (90) 
(ml.min )
1170
(90)
1250
(90)
H.P.F. 620 
icg _ (40) 
(ml .min”-1-)
610
(50)
560
(30)
Tl/2±v 225 
(11)
(min)
270*
(12)
213
(10)
E.R. 0.74 
(.03)
0.63*
(.03)
0.75
(.04)
% free 13.0 13.3 12.7
(1.1) (0.8) (0.9)
* p<0.05 compared with placebo
Pla Placebo phase 
Cim Cimetidine phase 
Enp Enprostil phase
H.P.F.prop Hepatic plasma flow propranolol method 
H.P.F.icg Hepatic plams flow ICG method
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Table XXVI
Propranolol and ICG 
Hepatic plasma flow
Placebo Cimetidine Enprostil
PROP ICG PROP ICG PROP ICG
1 1620 720 - 1600 800 1420 730
2 900 690 760 760 1250 590
3 1550 490 1440 640 1570 620
4 1150 690 1130 610 910 600
5 1210 440 850 410 1070 440
6 830 490 990 410 1160 590
7 930 730 1410 610 1650 58 0
8 1510 600 1170 450 1270 440
9 1190 740 1160 760 920 430
mean 1210 620 1170 610 1250 560
sem 90 40 90 50 90 30
Prop - Propranolol method 
ICG - Indocyanine green method
. -1
620 +/“ 40, 606 +/“ 50 and 557 +/“ 34 ml.min for
placebo, cimetidine and enprostil phases respectively.
A comparison between the hepatic plasma flow values 
calculated by the two techniques was made using the 
method of Bland and Altman (316) (Figure 27). This 
method is applied to comparison of two ways of measuring 
the same variable. In order to avoid the possible false 
positive correlation inherent in measuring the same 
variable, the mean value for each pair of measurements 
is plotted against the difference between the same pair. 
Applied to this study it demonstrates that the 
difference between the value calculated by the ICG and 
the propranolol method increases as hepatic plasma flow 
increases.
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7.1 Dog studies
The disposition of propranolol was altered markedly 
during anaesthesia. The degree of change was similar 
during all four anaesthetic regimens. The changes were 
still present 24 hours after halothane anaesthesia but 
had returned to control values in the other study 
groups.
The principal finding of these studies was the marked 
inhibition of intrinsic clearance that occurred during 
anaesthesia. The fall was of similar magnitude (35-50% 
of control) with all four anaesthetic regimens. As 
propranolol undergoes only oxidative metabolism in the 
liver, this represents an inhibition of the activity of 
the hepatic cytochrome P450 enzymes by the anaesthetic 
agents. The mechanism of this inhibitory action is not 
immediately apparent. To explain this action several 
potential mechanisms must be considered including a 
direct effect of the anaesthetic agents on the hepatic 
enzymes, the effect of the anaesthetic state on the 
local environment of the hepatocytes and cellular 
hypoxia. These possibilities will be addressed.
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7.1.1 Action on enzymes
The inhibition of the metabolic breakdown of a drug
by the hepatic oxidative enzymes due to the action of 
another drug was described first nearly 30 years ago 
(317,318). Since these first studies many inhibitory 
interactions have been described. For example, a large 
study by Kato and colleagues (319), using five test 
substrates including pentobarbitone, hexobarbitone and 
meprobamate, demonstrated the inhibitory action of some 
20 compounds and drugs on oxidative drug metabolism. 
More recently, the H2- receptor antagonist cimetidine 
has been shown to have an inhibitory action on the 
oxidative metabolism of many drugs. In anaesthesia an 
early study in this area of research demonstrated 
inhibition of pentobarbitone metabolism in rats both in 
vitro and in vivo by anaesthetic concentrations of
diethyl ether (320). This inhibitory effect on oxidative 
reactions has been demonstrated using the halogenated 
agents both in vitro with a rat hepatocyte preparation
exposed to halothane (10) and in vivo in rats during
exposure to halothane and isoflurane using the 
aminopyrine breath test (20).
At a cellular level, the mechanism of this action has 
not been established. The potential modes of action for 
an inhibitor of microsomal enzyme function have been
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outlined by Netter (321). These can be divided broadly 
into binding and chemical actions.
The possible actions due to binding include ;
a) binding of the inhibitor to the haem molecule and, 
therefore decreasing the oxygen binding capability. This 
effect is found with the inhibitor metyrapone (322) .
b) competition between a substrate and the agent for the 
substrate binding site. This has been demonstrated for 
many inhibitors.
c) the reaction produces a metabolite which exhibits 
prolonged binding to the active site. This has been 
demonstrated with piperonyl butoxide (323) .
The chemical actions on the microsomal enzyme system 
may include ;
a) inactivation of cytochrome P450 by transformation to 
cytochrome P420.
b) interference at a molecular level with the normal 
reactions involved in drug oxidation by inhibition of 
P-450 reduction
c) diversion of electrons from NADPH.
Competition for the substrate binding site is the 
most commonly described mechanism of drug interaction 
resulting in inhibition of metabolism and must be 
considered, therefore, as a possible explanation. It is 
interesting to note that, despite a very similar effect 
on propranolol metabolism, there is considerable 
difference in structure between the volatile anaesthetic
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agents and fentanyl. However, the drugs and compounds 
known to cause inhibition of the hepatic oxidative 
enzymes show an even more diverse range of chemical 
structure (324). The halogenated ether anaesthetic 
agents enflurane and methoxyflurane have been shown to 
bind to cytochrome P450 (325). A property which is
common to all four agents used in these studies is lipid 
solubility. This will allow these compounds to pass 
easily across the cell membrane into the cell and hence 
to the enzyme sites in the microsomes. It is possible 
that all of the agents may exert a similar effect on the 
microsomes which either inhibits the uptake of the 
substrate into the microsome or denies the substrate 
access to the enzyme site. This would be supported by 
the studies of Mather and colleagues (326) using a sheep 
model. They have noted that halothane anaesthesia causes 
a decrease in pethidine clearance but that 
bromsulphthalein clearance measured at the same time was 
unchanged despite a fall in hepatic blood flow. This may 
be explained by the different mechanisms involved in the 
elimination of pethidine and bromsulphthalein by the 
liver. Small basic drugs like pethidine enter the 
hepatocyte in their unbound form by diffusion down a 
concentration gradient and undergo oxidative metabolism. 
Large anions such as bromsulphthalein are transported 
into the cell while still bound to plasma proteins and 
usually undergo conjugative reactions. It would appear
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that the affinity of the conjugating enzymes for
bromsulphthalein is not altered by anaesthesia but that 
of the oxidative enzymes for pethidine is. As a side 
note this would suggest also that estimation of hepatic 
blood flow using indicator clearance methods must be
interpreted with caution.
As conjugation takes place mainly in the rough 
endoplasmic reticulum and oxidation in the smooth
endoplasmic reticulum the notion of a specific site of
action would be supported. In his in vitro studies 
using rat hepatocytes, Brown described a much smaller 
degree of depression of conjugative metabolism than of 
oxidative metabolism (11). However, Brown rejected lipid 
solubility as the sole mechanism of action on the 
grounds that halothane produced the same magnitude of 
depression of metabolism on three barbiturates which had 
lipid solubility coefficients ranging from 39 - 250.
Brown also noted the non-competitive nature of the
inhibition, an all or nothing action (10). The same 
effect is found in these studies where the scale of 
depression of metabolism is similar for all four agents. 
This arguement would appear to be against competition 
for enzyme sites being the basis for the inhibitory 
action, as a graded response might be expected.
At a molecular level it has been shown that the 
fluoridated hydrocarbons interfere with the normal
microsomal reactions. These compounds act $s
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pseudosubstrates which resist the action of the 
activated oxygen-cytochrome P450 complex but continue to 
stimulate NADPH oxidation (327-329). This uncoupling of 
the electron flow pattern may result in inhibition of 
the metabolism of other drugs.
It is interesting to note that, of the three 
inhalational agents, halothane produces a much longer 
acting effect on enzyme function. Halothane undergoes a 
much greater degree of metabolism in the body than the 
other volatile agents. Therefore, halothane and its 
metabolites will be present in the body for a longer 
time than the other drugs. The transient depression of 
metabolism by isoflurane has been described in other 
studies both in vitro (42,43) and in vivo (20). This 
supports the theory of a direct action of the agent or a 
metabolite on enzyme function, rather than an effect of 
anaesthesia per se.
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7.1.2 -Action of anaesthesia
The alterations in drug disposition may have resulted 
from changes produced by the state of anaesthesia, 
independent of the agent used. That is, the haemodynamic 
and metabolic changes which are a result of induction 
and maintenance of anaesthesia. This approach is 
supported by the finding that the change in the 
intrinsic clearance of propranolol produced during 
anaesthesia with fentanyl-atracurium-nitrous oxide was 
of the same magnitude as that produced with each of the 
inhalational anaesthetic agents. The haemodynamic and 
metabolic factors which may have influenced the 
disposition of propranolol will be considered.
The haemodynamic changes which may have occurred 
during the anaesthesia phase of these studies would 
result from the effect of controlled ventilation and 
from the effects of the individual agents on regional 
blood flow (330). During normal (spontaneous) 
respiration in the dog hepatic venous blood flow is the 
principal contribution to venous return during 
expiration (331). However, the pattern of venous return 
is altered by controlled (positive pressure) ventilation 
(332-334). This produces an increase in hepatic venous 
pressure and splanchnic vascular resistance which 
results in a decrease in hepatic blood flow
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(52,53,67,334,335). This effect is increased in the 
presence of hypocarbia (140,336). The effects of the 
various agents were summarised in Chapter 1. At an 
inspired concentration of 2MAC, halothane and enflurane, 
in the absence of surgery, appear to depress total 
hepatic blood flow to a similar degree, some 20-50% 
(55,140). Isoflurane at an inspired concentration of 
2MAC appears to have a smaller effect on total hepatic 
blood flow (59). The changes in total hepatic blood flow 
are due mainly to the decrease in portal flow which 
results from the decrease in cardiac output found during 
anaesthesia with these agents. The measured change in 
hepatic blood flow of 25-45% found in these studies was 
consistant with that described in other studies 
(52,53,55,140,334-338). This change was insufficient to 
account entirely for the change demonstrated in the 
clearance of propranolol. However, the decreased hepatic 
blood flow did contribute to the overall decrease in the 
measured systemic (intravenous) clearance. In addition, 
in the halothane study a similar degree of change to 
that found during anaesthesia was still present 24 hours 
after anaesthesia, at which time the dogs were awake and 
breathing normally. Further evidence that blood flow 
changes are only a minor mechanism for the change in 
disposition comes from studies using isolated perfused 
bovine liver (339). A fall in clearance occurred in the 
presence of anaesthesia despite the perfusing flow being
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held constant.
7.1.3 Hypoxia
An alteration in the normal hepatic metabolism 
resulting from anaesthesia or anaesthetic agents is a 
further possible mechanism. This could be due to an 
hypoxia at cellular level. In an isolated perfused rat 
liver preparation, the metabolic clearance of antipyrine 
has been shown to be related linearly to oxygen delivery 
and consumption (340). Systemic hypoxia was not present 
in any of the study animals as arterial blood gases were 
measured at regular intervals during each study. The 
inhalational agents were administered in oxygen alone, 
and 33% oxygen was used in the
fentanyl-atracurium-nitrous oxide study. Hyperoxia has 
been shown to have no effect on hepatic enzyme function 
(140).
However, it is possible that anaesthesia results in a 
relative intra-hepatic hypoxia and subsequent reduction 
in enzyme activity (341). Inhibition of propranolol and 
antipyrine elimination consistent with reduced hepatic 
enzyme function has been demonstrated during hypoxia in 
isolated perfused rat liver and hepatocyte preparations 
(340-344). This may be due to a redistribution of the 
intrahepatic blood flow or due to interference in the 
utilisation of oxygen by the hepatocytes. The effect of 
anaesthesia on the hepatic microcirculation is difficult
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to determine. It has been suggested that halothane can 
cause a selective hepatic arterial constriction 
(337,338). In contrast, isoflurane appears to preserve 
hepatic arterial flow but a similar effect on metabolism 
is found (59) . As the effect of hypoxia on drug 
metabolism can be detected in isolated, therefore 
denervated, perfused liver, it would appear more likely 
that the defect is in the utilisation of the oxygen by 
the hepatocyte.
Studies which have measured the hepatic oxygen 
supply, uptake and consumption during anaesthesia may 
support this theory. A fall in the oxygen supply to the 
liver, due to decreased hepatic blood flow, which is 
compensated for by an increase in the hepatic extraction 
of oxygen (an increased arterio-venous difference) 
resulting in no significant change in hepatic oxygen 
consumption has been demonstrated during anaesthesia 
with halothane (57,345,346), enflurane (57,62) and 
isoflurane (60). This would support the site of the 
defect being at the level of oxygen utilisation within 
the hepatocyte. This could be produced by the mechanisms 
suggested above such as binding to receptors or 
alteration of the cell membrane. Hepatic oxygen 
consumption and utilisation measurements were not made 
during this series of studies. However, a similar 
anaesthetic technique and dose of anaesthetic agent to 
that used in the studies described above was used in
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this series.
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7.1.4 Critique of methods
The mean hepatic plasma flow was calculated in these 
studies from plasma propranolol concentrations. In the 
dog the blood:plasma ratio for propranolol is 0.9 ; 
plasma concentrations are thus slightly greater than 
blood concentrations. Hence, the mean hepatic plasma 
flow measurements in these studies may be regarded as 
approximating to mean hepatic blood flow. The measured 
values are consistent with those previously described 
for the dog (57,59). T h e “changes demonstrated during 
anaesthesia are similar to those described in humans 
during anaesthesia and in the absence of surgery 
(52,53,55). Beta-adrenoceptor blockade has been shown to 
produce a fall in hepatic blood flow of up to 20% 
(348,349). In these studies the plasma propranolol 
concentrations were sufficient on all three study days 
to cause near maximal beta-adrenoceptor blockade. It is 
unlikely that the increase in propranolol concentration 
during anaesthesia would produce the measured decrease 
in hepatic plasma flow. Some previous studies in humans 
have described larger falls in hepatic blood flow during 
anaesthesia. These studies may have overestimated the 
change in hepatic blood flow if flow was calculated from 
the systemic clearance of an intravenouly administered 
indicator substance. This would occur if the hepatic
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extraction of the indicator also was decreased during 
anaesthesia. The hepatic extraction ratio at a fixed 
intrinsic clearance will increase as hepatic blood flow 
decreases (176). A similar series of lines describing 
the resultant curvilinear relationship between systemic 
clearance and hepatic blood flow demonstrates a shift to 
the right as extraction ratio decreases. If, in the 
presence of a decrease in extraction, hepatic blood flow 
was calculated using the new systemic clearance value 
and the original extraction ratio a falsely low value 
for hepatic blood flow would be obtained.
The change in the systemic clearance during 
anaesthesia therefore reflects the changes in both 
hepatic blood flow and intrinsic clearance. For drugs of 
very high hepatic extraction, systemic clearance and 
hepatic blood flow have a near linear relationship (Cls 
= QE) and intrinsic clearance is independent of hepatic 
blood flow. However, as extraction ratio decreases, the 
influence of hepatic enzyme function in determining 
systemic clearance gradually increases. As Cls = 
(1-E)Clint, it can be seen that if E is very small Cls = 
Clint. This is shown in the results of these studies 
where the change in systemic clearance is too large to 
be explained by change in hepatic blood flow alone. The 
inter-relationship of these three variables can be 
illustrated using the results of the halothane study. 
The change from Day 1 to Day 2 in the values for
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systemic clearance and hepatic blood flow are influenced 
by the change in hepatic extraction and provide a unique 
solution for the relationship on each Day (Figure 28). 
From the calculated systemic clearance on Day 2 (Point 
A) , hepatic blood flow calculated assuming the 
extraction ratio had not changed would derive a much 
lower value (Point B) than that which takes account of 
the decrease in hepatic extraction (Point C).
Anaesthesia with halothane, enflurane and fentanyl- 
atracurium- nitrous oxide caused an increase in the free 
fraction of propranolol of 2-4%. This had returned
towards the pre-anaesthetic value within 24 hours. The
effect was not seen during isoflurane anaesthesia. The 
change demonstrated represents an increase of 20-30% in 
the unbound propranolol. A change of this magnitude has 
important implications regarding the potential for 
toxicity of drugs present during anaesthesia. The free 
fraction of propranolol during the study period is lower 
than has been described previously where levels of 
15-25% have been found. The lower values found in these
studies are consistent with the increase in acute phase
reactant proteins, such as alpha 1-acid glycoprotein, 
which would be expected following the surgery to place 
the cannulae five days earlier (110,350,351). This is 
supported by the finding that samples taken from some 
dogs before the surgery demonstrated a free fraction of 
propranolol of around 15%. Any variability in the
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The lines describe the relationship between
systemic clearance and hepatic blood flow with a
fixed extraction ratio (Day 1 0.75, Day 2 0.60).
Using the calculated Cl for Day 2 (Point A) thes
derived hepatic blood flow would be falsely low 
(Point B) if it was assumed E.R. had not changed. 
Point C takes account of the change in E.R.
response to surgery was minimised by starting the study 
with all dogs on the fifth day after surgery. Plasma 
concentrations of alpha 1-acid glycoprotein were not 
measured in these studies.
The change in clearance of propranolol, as there is 
no change in volume of distribution, is reflected in a 
prolongation of the elimination half-life of 
propranolol.
The methods used in these studies were designed to 
allow comparison within each study group and between 
groups. The design was successful in the control, 
halothane, isoflurane and fentanyl groups but problems 
were encountered with the enflurane study. The dogs were 
unable to tolerate enflurane at 2 MAC in the presence of 
beta-adrenergic blockade. Even when the dose of 
propranolol was reduced and the enflurane reduced to 1.5 
MAC, three of the five dogs were not fit enough for a 
third study day. The cardiac depressive effects of 
higher doses of enflurane in dogs has been noted by 
other workers (57). These changes in protocol make it 
difficult to compare directly the results of the 
enflurane study with the others. -However, the scale of 
change in the pharmacokinetic variables is similar to 
that in the other studies in this series.
The time between surgery for cannulation of the 
vessels and the pharmacokinetic study was five days in 
all animals. The post-surgical changes, discussed in the
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introduction, of increased protein binding and a small 
increase in clearance which has been ascribed to enzyme 
induction by some workers (7-9), would be present at 
this time. However, these changes would be fairly stable 
throughout the study period (110) and are relatively 
small in comparison to the changes produced in the 
pharmacokinetic variables by anaesthesia. For example, 
the free fraction of propranolol which decreased between 
surgery and the study days demonstrated an increase 
during anaesthesia in all the studies with a return to 
control value 24 hours later.
The metabolic state at the time of study has been 
shown to influence the pharmacokinetic of some drugs 
(289,290). All the dogs were fed with the same brand of 
dog food and biscuits at set times in relation to the 
study to minimise any influence of this variable.
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7.1.5 Recent studies
Several other studies of the effect of anaesthesia on 
drug disposition have appeared since this project was 
started. Runcieman and Mather have developed a 
chronically cannulated sheep model with which the have 
looked at hepatic drug clearance of chlormethiazole, 
pethidine and mepivacaine (28,352-356). With this model 
they have evaluated the changes produced by anaesthesia 
using volatile agents and intravenous agents such as 
propofol. A similar pattern of altered disposition has 
been found with all these techniques and the extent of 
change is comparable to that found in this series of 
studies. Using halothane anaesthesia at 1.5 MAC in the 
sheep, the mean hepatic clearance of pethidine fell to 
60% of control value. A decrease of similar magnitude 
was described for enflurane and isoflurane anaesthesia. 
Both propofol and thiopentone, by infusion, produced a 
reduction in the hepatic clearance of pethidine of 
around 20% (37). These workers also described changes in 
renal and pulmonary drug clearance during anaesthesia 
which was ascribed to altered excretion and blood flow.
Merin and co-workers have shown that the disposition 
of verapamil in the dog is altered during anaesthesia to 
an extent similar to that described here for propranolol 
(25,358). In the presence of halothane,isoflurane or
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enflurane anaesthesia, the clearance of verapamil is 
reduced by about 40% and the apparent volume of
distribution decreased by 35%. Hepatic blood flow was 
not measured in these studies, but the cardiovascular 
effects of verapamil were potentiated by higher
concentrations of halothane anaesthesia (358). 
Intravenous lignocaine produced an increase in the 
apparent volume of distribution and in the clearance of 
verapamil (359). In a separate study this group
demonstrated no change in hepatic arterial blood flow
and a 35% fall in portal blood flow during enflurane 
anaesthesia in dogs (360). Isoflurane anaesthesia has 
been shown to produce a significant decrease in total 
hepatic blood flow with no change in oxygen consumption 
resulting in lower hepatic venous and hepatic surface 
oxygen tensions (361).
Further studies have been undertaken in Vanderbilt 
University using the same canine model. It has been
shown that anaesthesia using a continuous infusion of
propofol produces an effect on the disposition of 
propranolol (362). A 40% reduction in the intrinsic 
clearance of propranolol was produced but there was no
change in hepatic blood flow. There was a significant 
increase from 8.5 to 14.0% of the free fraction of 
propranolol during propofol anaesthesia. In addition, 
the study with halothane anaesthesia has been repeated 
with a refinment of the HPLC analysis which allows
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detection of both isomers of propranolol (363). The 
overall effect was the same as in the original study but 
it was found that the metabolism of the 
pharmacologically active 1-isomer was much more markedly 
inhibited (75%) than that of the d.-isomer (63%) . In 
contrast, spinal anaesthesia with tetracaine produced no 
significant effect on propranolol disposition in the dog 
(364). The acute effect of halothane anesthesia on the 
disposition of morphine has been studied with a similar 
canine model (365,366). Halothane anaesthesia produced a 
decreased hepatic clearance of morphine which was 
ascribed to the decrease in hepatic blood flow and not 
to a decrease in metabolic clearance as the hepatic 
extraction of morphine increased during anaesthesia. The 
authors concluded that halothane has less effect on 
conjugative than on oxidative metabolism.
A series of studies in the rat has shown a comparable 
effect on lignocaine and propranolol metabolism (367). 
Halothane, enflurane and isoflurane all produced a 
similar degree of depression of propranolol clearance. 
However, isoflurane had a smaller effect on lignocaine 
clearance than halothane or enflurane.
The effect of infusion of intravenous anaesthetic 
agents on canine hepatic blood flow has been studied by 
Thomson and colleagues (368). A dose related decrease in 
hepatic blood flow was found with infusion of
thiopentone, althesin or etomidate. With Althesin and
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etomidate infusions at low rates hepatic arterial flow 
appeared to decrease before systemic effects were found. 
Etomidate has been shown to have a reversible inhibitory 
effect on in vitro rabbit hepatocyte cytochrome P450 
activity resulting from binding of etomidate to the 
cytochromes (369) .
These studies suggest that anaesthesia produced by 
either the inhalational or by the intravenous agents 
appears to produce a reduction in hepatic drug 
metabolising enzyme activity. The effect is dose related 
but appears to be of a consistent magnitude across a 
number of study groups and species. The effect is 
greater than can be explained by changes in hepatic 
blood flow. An increased pharmacological effect has been 
demonstrated with some test drugs.
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7.1.6 Summary
The studies described here have demonstrated that 
general anaesthesia using a volatile agent or a balanced 
anaesthesia technique, alters significantly the 
disposition of propranolol. This effect would appear to 
be of a similar magnitude for all the agents but is 
present for a longer period post-operatively following 
halothane anaesthesia. Propranolol is a drug of high 
hepatic extraction which undergoes oxidative metabolism 
in the liver, which, when given simultaneously 
intravenously and intraportally, can be used to define 
the metabolic and flow dependent elements of hepatic 
drug clearance. The principal effect of anaesthesia was 
a marked inhibition of the rate of metabolism of 
propranolol. The action of the anaesthetic agents 
appears to be an inhibition of the cytochrome P450
system, which is responsible for oxidative drug
metabolism. At a cellular level, the mechanism of this 
change is not fully understood but appears to involve 
impairment of the utilisation of oxygen by the
microsomes. The clinical significance of this effect is 
an increase in the bioavailability of, a rise in the 
plasma concentrations and a prolongation of the 
elimination of propranolol. It has become more common to 
continue concurrent drug therapy throughout the period
190
of operation. If, as is likely, anaesthesia has a 
similar effect on other drugs which undergo hepatic 
oxidative metabolism care must be exercised to alter the 
dosage schedule of drugs which are continued through the 
peri-operative period.
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7.2 . Human study
This study demonstrated a reduction in the clearance 
of propranolol administered orally which was consistent 
with a reduction in hepatic drug metabolising 
capability. No effect on hepatic blood flow was found. 
The prostaglandin analogue, enprostil appeared to have 
no effect on enzyme activity or hepatic blood flow.
Cimetidine has been shown to impair the elimination 
of a large number of drugs (221) including propranolol 
(275,276). This study -.confirms that the
co-administration of cimetidine reduces the oral 
clearance of propranolol due to inhibition of hepatic 
oxidative enzyme activity. This results in increased 
bioavailability and elevation of plasma concentrations 
of propranolol.
Previous studies have demonstrated conflicting 
conclusions on the effect of cimetidine on hepatic blood 
flow. Some studies have suggested that cimetidine causes 
a decrease in hepatic blood flow (275,296) and some have 
found a similar effect with ranitidine (370,371). Other 
investigators have, however, failed to demonstrate any 
consistent effect of the H2 antagonists on hepatic blood 
flow (301,303). The results of these previous studies 
are difficult to interpret as many used small numbers of 
patients, did not include a placebo control, were not
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double-blind and did not randomise the order of drug 
administration. Considerable interindividual variation 
in the baseline hepatic blood flow was found. This study- 
involved nine subjects who received the drugs and placebo 
in a double-blind, randomised fashion with a balanced 
order of drug administration. Using this design we 
demonstrated no effect of cimetidine on hepatic blood 
flow.
The role of prostaglandins in the control of drug 
metabolising activity is poorly defined. In vitro 
studies have suggested that prostaglandins can alter 
the hepatic metabolism of a number of drugs including 
benzpyrine, aminopyrine and hexobarbitone (309,310). The 
haemodynamic effects of prostaglandins are defined more 
clearly. Gastric blood flow appears to be partially 
under the control of prostaglandins as it is altered by 
the administration of the cyclo-oxygenase inhibitors 
aspirin and indomethacin (306,307). A reduction in the 
clearance of indocyanine green, which was attributed to 
a reduction in hepatic blood flow has been demonstrated 
in man following aspirin or indomethacin administration 
(372). The prostaglandin analogue, enprostil, may have 
been expected to cause a decrease in either hepatic 
enzyme activity or in hepatic blood flow. However, no 
effect was demonstrated on either variable.
Two different methods of estimation of hepatic blood 
flow were used in this study. The value for hepatic
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blood flow measured by dual-route propranolol was 
consistently higher than that measured using indocyanine 
green clearance. This has not been remarked on before 
but review of other published data appears to confirm 
this finding(275,296,373). The explanation of this
difference is not immediately clear. It must be noted 
that the two methods measure hepatic blood flow over 
quite different time periods. The indocyanine clearance 
was measured over a 20 minute period after the subjects 
had been resting for 1 hour following an overnight fast. 
The propranolol method measures the hepatic blood flow 
over a prolonged period with sampling continued for 8 
hours and the time-concentration curve extrapolated from 
the last data point. It is likely that there was an 
increase in blood flow after the subjects were fed at 
4-5 hours into the study period. The estimation of 
hepatic blood flow using indocyanine clearance assumes a 
hepatic extraction of 100%. Considerable interindividual 
variation has been shown in the hepatic extraction of 
ICG with many subjects having extraction ratios of less 
than 100% (168,169). The ICG method will therefore tend
to underestimate hepatic blood flow. The difference in 
estimated blood flow between the two methods appears to 
increase as hepatic blood flow increases.
This study is included to demonstrate the feasability 
of using the dual-route administration method for 
studies in man in the peri-operative period. A known
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enzyme inhibitor was administered to the subjects to 
test the ability of the method to detect the resultant
change in oral clearance. Hepatic blood flow was
unchanged by the drugs used but consistent values were 
found for the subjects and these appear to be more 
reproducable than those estimated from indocyananine
green clearance. It is clear that propranolol is not an 
appropriate drug for administration to patients
undergoing surgery and anaesthesia but other drugs of 
similarly high hepatic extraction but with much less 
systemic effect would be suitable model drugs with which 
to apply this methodology to studies in man during the 
peri-operative period.
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APPENDICES
Pharmacological Abbreviations
Xdiv - Dose of drug given intravenously
AUCiv - Area under the time-concentration curve for
intravenous drug to infinity 
Xdp - Dose of drug given portally
AUCp - Area under time-concentration curve for
portal drug to infinity 
Xdo - Dose of drug given orally
AUCo - Area under time concentration curve for
oral drug to infinity 
Cls - Systemic or intravenous clearance
Clp - Apparent portal clearance
Clint - Intrinsic clearance
Cliv - Intravenous clearance
E - Hepatic extraction ratio
F - Bioavailability
Tl/2iv - Elimination half-life
k - Elimination rate constant
Vb - Apparent volume of distribution after
equilibrium is achieved 
HPF - Hepatic plasma flow
fb - Fraction of bound drug
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In s t i t u t e  o f  C l in ic a l  M e d ic in e  
3 4 0 1  H i l lv ie w  A v e n u e  
P a lo  A l t o ,  C a l i fo r n ia
C O N S E N T
E N P R O S T IL  ( R S -8 4 1 3 5 -0 0 -0 0 -3 )  A N D  C IM E T ID IN E :
A  C O M P A R IS O N  O F  E F F E C T S  O N  H E P A T IC  B L O O D  F L O W
E x p la n a tio n  o f  S tudy
I u n d e rs ta n d  t h a t  I  h a v e  b een  a sked  to  p a r t ic ip a te  in a f iv e  w e e k  re s e a rc h  s tu d y  th a t  w i l l  
in v o lv e  a m a x im u m  o f  n in e  h e a lth y  m a le  v o lu n te e rs . T h e  p u rp o se  o f  th is  s tu d y  is to  
e v a lu a te  and  c o m p a re  th e  e f f e c ts  o f  a m a r k e te d  d ru g  (c im e t id in e )  and an  in v e s t ig a t io n a l  
drug  (e n p ro s t il)  on th e  r a te  a t  w h ic h  b lo o d  f lo w s  th ro u g h  m y  l iv e r .  T h e s e  drugs w i l l  b e  
c o m p a re d  to  a p la c e b o , w h ic h  is in a c t iv e .
I  u n d e rs ta n d  t h a t  no o th e r  d ru g s , a lc o h o l, a s p ir in  p ro d u c ts , c o f f e e  o r c a f fe in e  p ro d u c ts  
should  be con su m ed  7 2  h ours  b e fo r e  a d m iss io n  to  th e  s tu d y  o r d u rin g  th e  s tu d y .
P ro c e d u re s
I u n d ers ta n d  t h a t  th is  s tu d y  is d iv id e d  in to  th r e e  (3 ) s ix  d a y  p hases . I  w i l l  r e c e iv e  e a c h  one  
o f  th e  s tu d y  m e d ic a tio n s  o n c e . P r io r  to  phase one I  w i l l  h a v e  c o m p le te  p h y s ic a l and  
la b o r a to r y  e x a m in a t io n s . T h e  p h y s ic a l e x a m  w i l l  b e  r e p e a te d  a t  th e  e n d  o f  th e  s tu d y  
w h ile  th e  la b o r a to ry  e x a m  w i l l  b e  r e p e a te d  a t  th e  c o n c lu s io n  o f  e a c h  p h a s e .
I u n d e rs ta n d  th a t  in  o rd e r  to  m e a s u r e . m y  l iv e r  b lood , f lo w  I  w i l l  be  in je c te d  w ith  an  
in d ic a to r  d ye  c a lle d  IC G  on d ay  5 and  a c a rd io v a s c u la r  d ru g  c a lle d  p ro p ra n o lo l on d ay  6 . 
IC G  is c o m m o n ly  used to  s tu d y  l iv e r  fu n c t io n . P ro p ra n o lo l is w id e ly  p re s c r ib e d  fo r  h igh  
b lood  p ressu re  and is re m o v e d  f r o m  th e  b lo o d  p r im a r i ly  by  th e  l iv e r .  I  u n d e rs ta n d  t h a t  
b lo o d  sam p les  w i l l  be d ra w n  a t  th e  fo l lo w in g  in te rv a ls :  D a y  5 a t  1, 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 1-0, 
12, 15 and 20  m in u te s ; D a y  6 a t  0 , 5 , 15, 2 0  m in u te s  and 1, 2 , 3 , 4 , 5 , 6 , 7 a n d  8 h o u rs .
R is ks  and P re c a u tio n s
I u n d e rs ta n d  t h a t  e n p ro s ti l shou ld  n o t  b e  h a n d le d  by a s th m a t ic s  o r  p re g n a n t  w o m e n . I t  
s h o u id .b e  k e p t  o u t o f  re a c h  o f  c h i ld re n . I  u n d e rs ta n d  t h a t  s id e  e f f e c ts  t h a t  m ig h t  o c c u r  
d u rin g  th is  s tu d y  c o u ld  in c lu d e  w h e e z in g , n a u s e a , v o m it in g , d ia r r h e a , h e a d a c h e , w a rm  
fe e lin g  in  th e  s to m a c h , s to m a c h  c ra m p s  and  s lig h t ly  in c re a s e d  r is k  o f  b lo o d  c lo t t in g .  
O th e r ,  p re v io u s ly  u n re p o r te d  o r  u n k n o w n , s ide  e f f e c ts ,  in c lu d in g  d ru g  a l le r g y ,  m a y  a lso  
o c c u r .
D u r in g  th e  c o l le c t io n  o f  b lo o d  s a m p le s , I  m a y  e x p e r ie n c e  p a in  a n d /o r  b ru is in g  a t  th e  s ite  
on m y  a rm  w h e re  b lo o d  is d ra w n . L o c a l in fe c t io n s  m a y  r a r e ly  o c c u r .
B e n e fits
I c a n n o t e x p e c t  any  b e n e f its  f r o m  m y  p a r t ic ip a t io n  in th is  s tu d y .
W ith d ra w a l f r o m  S tu d y
I a c k n o w le d g e  th a t  m y  p a r t ic ip a t io n  in th is  re s e a rc h  p r o je c t  is v o lu n ta r y  and  t h a t  I h av e  
th e  r ig h t  to  w ith d ra w  a t  an y  t im e .  I t  has b een  e x p la in e d  to  m e  th a t  i f  th e  s tu d y  p h y s ic ia n  
fe e ls  t h a t  i t  is in m y  b e s t in te r e s t  to  be w ith d ra w n  f ro m  th e  s tu d y , h e  w i l l  do so 
im m e d ia te ly .  I fu r th e r  u n d e rs ta n d  th a t  m y  p a r t ic ip a t io n  in  th e  s tu d y  m a y  b e  e n d e d  a t  a n y  
t im e  w ith  o r w ith o u t  m y  c o n s e n t.
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M e d ic a l C a r e /P r o b le m s  R e la te d  to  th is  S tu d y
I  u n d e rs ta n d  th a t  in  th e  e v e n t  I  s u f fe r  any  m e d ic a l p ro b le m  w h ic h , in  th e  o p in io n  o f  th e  
in v e s t ig a to r ,  is r e la te d  to  th is  c l in ic a l  s tu d y  o r to  th e  p r e l im in a r y  p h y s ic a l e x a m in a t io n  o r  
la b o r a to r y  w o rk , e m e rg e n c y  m e d ic a l c a re  w i l l  b e  p ro v id e d  a t  no c h a rg e  to  m e . H o w e v e r ,  
no o th e r  c o m p e n s a tio n  is a v a i la b le .  I  m a y  o b ta in  m e d ic a l t r e a tm e n t  f r o m  th e  s tu d y  
p h y s ic ia n  o r he  w i l l  a ss is t m e  in  o b ta in in g  t r e a t m e n t .  I  h a v e  b ee n  ass u red  th a t  e v e ry  
e f f o r t  w i l l  be  m ad e  to  p r e v e n t  a n y  in ju ry  th a t  c o u ld  re s u lt  f r o m  th is  s tu d y  by th e  s tu d y  
p h y s ic ia n .
I  u n d e rs ta n d  th a t  i f  a n y  q u es tio n s  a r is e  r e la te d  to  th is  s tu d y  o r to  re s e a rc h  s u b je c ts ’ r ig h ts
I  a m  to  c o n ta c t  th e  s tu d y  p h y s ic ia n  ( D r .  ) a t  th e  fo l lo w in g  ph o ne
n u m b e rs ______________________________ .
R e le a s e  o f  M e d ic a l R e c o rd s
I  u n d e rs ta n d  th a t  i t  m a y  be  n e c e s s a ry  f o r  th e  U n ite d  S ta te s  F o o d  and  D ru g  A d m in is tr a t io n  
to  in s p e c t m y  m e d ic a l re c o rd s  as th e y  r e la te  to  th is  s tu d y . I  th e r e fo r e  c o n s e n t to  t h e  
re le a s e  o f  m y  m e d ic a l re c o rd s  to  S y n te x  o r  o th e r  r e g u la to r y  a g e n c ie s  w ith  th e  
u n d e rs ta n d in g  th a t  th e s e  re c o rd s  w i l l  be used o n ly  in c o n n e c tio n  w i t h  c a r ry in g  o u t  
o b lig a tio n s  r e la t in g  to  th is  c l in ic a l  s tu d y  and t h a t  th e y  s h a ll n o t be  used  fo r  any  o th e r  
p u rp o se .
C o n f id e n t ia l i t y
S y n te x  w i l l  n o t d isc lo se  th e  c o n te n ts  o f  m y  m e d ic a l re c o rd s  to  a n y  o th e r  p a r ty  o th e r  th a n  
th e  F o o d  and D ru g  A d m in is t r a t io n .  I  u n d e rs ta n d  th a t  a r e p o r t  o f  th e  re s u lts  o f  th is  s tu d y  
w i l l  be m a d e  to  th e  U n ite d  S ta te s  F o o d  and D ru g  A d m in is tr a t io n  and p o ss ib ly  to  o th e r  
re g u la to ry  a g e n c ie s  w ith  c o n f id e n t ia l i t y  o f  s u b je c t  id e n t i f ic a t io n  p re s e rv e d . T h e  re s u lts  
o f  th e s e  s tu d ie s  m a y  a lso  be used fo r  m e d ic a l and  s c ie n t i f ic  p u b lic a t io n  b u t  m y  id e n t ity  
w il l  n o t be d is c lo s e d .
C o n s e n t
B e fo re  g iv in g  m y  c o n s e n t by s ig n in g  th is  fo r m , I  h a v e  re a d  i t  and  I h av e  b e e n  s u f f ic ie n t ly  
in fo rm e d  o f  th e  drugs used , th e  in c o n v e n ie n c e s , th e  h a z a rd s , d an g e rs  and  a d v e rs e  e f f e c t s  
t h a t  m ig h t  o c c u r  f ro m  th e  use o f  th e  drugs d e s c r ib e d  in  th e  c o n s e n t fo r m . I  h a v e  spoken  
d ir e c t ly  to  th e  s tu d y  p h y s ic ia n  w ho  has a n s w e re d  to  m y  s a t is fa c t io n  a l l  o f  m y  q u e s tio n s  
c o n c e rn in g  th is  s tu d y . B ased  on th is  in fo r m a t io n  I v o lu n ta r i ly  a g re e  to  p a r t ic ip a te  in th is  
s tu d y . I  h av e  re c e iv e d  a s ig ned  co p y  o f  th e  c o n s en t fo r m .
P a t ie n t 's  S ig n a tu re  D a t e
S tu d y  P h y s ic ia n ’s S ig n a tu re  D a t i
W itn ess  S ig n a tu re  D a t e
IC M /3 5 6 8 u
4
S C H E D U L E  O F  E V E N T S
P h a s e
7 2  H o u r s I I I I I I
P r i o r  a n d  
D u r i n q  S t u d y B a s e l i n e D a y  1  D a y  6 D a y  1 5  D a y  2 0 D a y  2 9  D a y  3 4  F o l l o w - U p * *
s / A l c o h o l  ' X
L a b o r a t o r y  T e s t s * X X X X
1  E x a m i n a t i o n * * X X
o n X
d  C o n s e n t X
x  W e e k X X X
3 h a s e X X X
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